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Table I.I: Description of the oligonucleotides used in the project. 
Modifications, complementary, sequences and symbols. 
 
 
5’ 
MODIFICATION 
SEQUENCE SYMBOL 
a Thiol 5’-ACTATTCCCGGGTAATGA-3’  
aF 6-FAM 5’-ACTATTCCCGGGTAATGA-3’  
a' - 5’-AATTCATTACCCGGGAATAGT-3’  
A 
Thiol 
- 
5’-ACTATTCCCGGGTAATGA-3’ 
3’-TGATAAGGGCCCATTACTTAA-5’  
AF 
6-FAM 
- 
5’-ACTATTCCCGGGTAATGA-3’ 
3’-TGATAAGGGCCCATTACTTAA-5’  
m P 5’-ATTCCAAAGCTTCCCCCTA-3’  
m' 6-FAM 5’-TAGGGGGAAGCTTTGG-3’  
MF 
- 
6-FAM 
5’-ATTCCAAAGCTTCCCCCTA-3’ 
3’-GGTTTCGAAGGGGGAT-5’  
b Thiol 5’-GGGTAATGA-3’  
b' - 5’-AATTCATTACCC-3’  
B 
Thiol 
- 
5’-GGGTAATGA-3’ 
3’-CCCATTACTTAA-5’  
PEG-a mPEG20kDa-Mal 5’-ACTATTCCCGGGTAATGA-3’  
PEG-SS-a mPEG20kDa-OPSS 5’-ACTATTCCCGGGTAATGA-3’  
PEG-b mPEG20kDa-Mal 5’-GGGTAATGA-3’  
PEG-A 
mPEG20kDa-Mal 
- 
5’-ACTATTCCCGGGTAATGA-3’ 
3’-TGATAAGGGCCCATTACTTAA-5’  
PEG-SS-A 
mPEG20kDa-OPSS 
- 
5’-ACTATTCCCGGGTAATGA-3’ 
3’-TGATAAGGGCCCATTACTTAA-5’  
PEG-B 
mPEG20kDa-Mal 
- 
5’-GGGTAATGA-3’ 
3’-CCCATTACTTAA-5’  
 
 
 
 
  
 
 
 
1 ABSTRACT 

Abstract 
 
 3 
 
 
Since the early 80’s the forward steps in genetics and proteomics, have led a 
particular interest to biotech products, such as DNA and proteins. Although 
difficult, their large-scale production enabled the therapeutic use of this 
compounds. Proteins and DNA sequences can be very interesting therapeutic 
molecules owing to their high selectivity/affinity for the receptor or the specific 
site of action. 
Unfortunately, some issues still limit their pharmaceutical use, such as the 
susceptibility to enzymatic degradation, rapid renal clearance and 
immunogenicity. 
 To overcome these limitations, many researchers are seeking solutions in 
the field of drug delivery systems (DDSs). In this respect, many systems have 
been developed and conjugation with PEG (polyethylene glycol) can be 
considered one of the leading approaches. PEGylation brings to the conjugated 
molecule great solubility and stability to proteolytic digestion, furthermore it 
reduces the tendency to aggregate and reduces the immunogenicity. Thanks to 
these advantages and the particular characteristics of PEG, to date, there are on 
the market 12 pegylated compounds: 9 are proteins, one peptide, one aptamer 
and a liposomal formulation, containing doxorubicin. 
The improvements in the pharmacokinetic profile of these drugs, thanks to 
the use of drug delivery systems, can be also applied in the field of tissue 
engineering, where the same issues are of fundamental importance for the 
development of scaffolds for cells capable of releasing growth factors. 
In the last years various polymers have been studied by many research 
groups to find an alternative to PEG, but its excellent biocompatibility and the 
know-how in its use has not brought any polymer to be truly competitive 
against PEG. Nevertheless, PEG presents some limits such as its non-
biodegradability and in some case there are reports of antibodies against PEG. 
Therefore, there is an increased need for a PEG substitute. 
In the first section of this work hyaluronic acid (HA) has been studied as a 
candidate polymer for bioconjugation of proteins (HAylation). HA, being 
biodegradable can compensate this limit of PEG. HA, is also present in humans 
and is metabolized by hyaluronidase. Moreover, HA has the advantage of a 
high loading compared to PEG, thanks to the presence of repetitive functional 
groups in each monomer. 
This part of the work was focused on the study of HA conjugation  
(HAylation) to two model enzymes, trypsin and Ribonuclease A, and then to 
an interesting protein in pharmaceutical field, insulin. 
In order to avoid cross-linking phenomena, only a fraction of all carboxyl 
groups of the polymer has been modified to aldehyde allowing the conjugation 
with the amino groups of the protein models. Furthermore, by modulating the 
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pH of reaction two protein-HA conjugates were obtained, selective N-terminal 
(pH 6) or random (pH 8), this taking advantage of the different pKa values of 
the amino groups in the proteins. 
The first products obtained with the enzymes Ribonuclease A and trypsin 
were tested verifying the residual activity compared to the native proteins. All 
conjugates, in particular those obtained by N-terminal selective conjugation, 
maintain a good activity on small substrates (30% decrease); only the HA-
derived trypsin retains about 60% of residual activity against the substrate with 
a high weight molecular. Furthermore, enhanced stability over time was found 
for HA-trypsin respect to the free enzyme (45% on average) and also 
susceptibility to hyaluronidase was confirmed for both conjugates. 
Polymer validation as potential protein carrier was then evaluated by 
preparing conjugates with bovine insulin, as an example of pharmacologically 
active protein. Two conjugates were synthesized by N-terminal selective 
conjugation starting from polymers with different degree of aldehyde 
derivatization, 4% and 21%, yielding products with a protein loading of 17% 
and 32% (w/w), respectively. 
The therapeutic efficacy of the conjugates in comparison with insulin was 
tested in Sprague Dawley rats with induced diabetes. The conjugate with a 
lower protein loading was more effective and with a longer pharmacodynamic 
effect on the reduction on blood glucose level. 
The second section of the work was focused on an innovative strategy of 
enzymatic PEGylation of oligonucleotides. Briefly, the method investigated on 
model oligonucleotides is composed of two steps: the first consists in the 
chemical conjugation of a short oligonucleotide to a PEG chain, the second 
step is the enzymatic-mediated conjuagation of the PEGylated oligonucleotide 
with a DNA sequence by the DNA T4 ligase. 
To study the enzymatic PEGylation, 4 oligo sequences have been prepared 
as ligation model: two complementary pairs ending with sticky-ends in turn 
complementary (18-mer + 21-mer and 16-mer + 19-mer). The 18-mer has a 
thiol group in 5’-ending, in order to perform the coupling with PEG. 
Applying some modifications to ligation classical protocols, excellent 
results were obtained: PEGylated portion completely ligate the other ds-DNA 
and no undesired products were found. 
To further confirm the effective ligation, the ligated and PEGylated 
sequence was restricted with EcoRI. Indeed, the EcoRI recognized a sequence 
that is present only the ligated DNA. Complete restriction was found in 
absence and even in the presence of the polymer, further confirming the 
successes of ligation. 
Furthermore it was investigated if a reduced number of bases coupled to 
PEG can still preserve the requirements for the ligase enzyme activity. Thus, 
the pair of the complementary sequences then coupled to PEG has been 
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reduced to half (9-mer + 12-mer). Even with a shorter PEGylated sequence a 
complete ligation was obtained. 
In conclusion in this thesis it has been demonstrated that HA can be a valid 
alternative to PEG for protein conjugation. 
In the field of oligonucleotide delivery an enzymatic approach of 
oligonucleotide conjugation can open new horizons that so far have not been 
completely explored. 
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Dai primi anni 80 i passi avanti fatti nel campo della genetica e della 
proteomica, hanno portato ad un particolare interesse nei confronti dei prodotti 
biotecnologici, quali DNA e proteine. L’utilizzo terapeutico di queste entità, 
seppur non privo di difficoltà, è stato facilitato dalla loro produzione su larga 
scala. Proteine e sequenze oligonucleotidiche si sono rivelate interessanti come 
agenti terapeutici essendo molecole dotate d’elevatissima selettività/affinità per 
il recettore o il sito d’azione specifico. 
L’impiego farmaceutico può evidenziare alcuni svantaggi che ne possono 
limitare l’utilizzo, come ad esempio la suscettibilità alla degradazione da parte 
di proteasi e DNasi, la rapida clearance renale e l’immunogenicità. 
Per affrontare tali limiti, molti ricercatori hanno cercano soluzioni nel 
campo dei drug delivery sistems (DDSs). A tal proposito, sono stati sviluppati 
molti sistemi e la coniugazione al PEG (polietilen glicole) è risultata essere una 
delle più promettenti. La PEGhilazione, infatti, conferisce alle molecole 
coniugate maggiore solubilità e stabilità nei confronti della digestione 
proteolitica, una ridotta tendenza all’aggregazione ed una ridotta 
immunogenicità. Grazie a questi vantaggi ed alle particolari caratteristiche del 
PEG, ad oggi sono presenti nel mercato 12 composti PEGhilati: 9 sono 
proteine, un peptide, un aptamero ed una formulazione liposomiale (contenente 
doxorubicina). 
Le migliorie apportate ai profili farmacocinetici di questi farmaci biotech 
grazie all’uso di DDSs possono essere anche impiegate nel campo 
dell’ingegneria tessutale, dove le medesime problematiche sono di basilare 
importanza per lo sviluppo di scaffold per cellule, in grado di rilasciare fattori 
di crescita. 
Il polietilen glicole (PEG) è il polimero leader per la coniugazione di 
proteine. Negli ultimi anni diversi polimeri sono stati studiati per trovare una 
valida alternativa a questo polimero, ma la sua eccellente biocompatibilità e la 
conoscenza nel suo utilizzo non ha ancora portato nessun polimero ad essere 
realmente competitivo nei suoi confronti. Nonostante tutto, anche l’utilizzo del 
PEG presenta alcuni limiti, quali la non-biodegradabilità e la documentata 
presenza di anticorpi anti-PEG sviluppati in alcuni casi specifici. Per questo 
motivo si è alla ricerca di un polimero che possa validamente sostituire il PEG. 
Nella prima parte di questo lavoro di tesi è stato studiato l’acido ialuronico 
(HA) per la bioconiugazione di proteine (HAylation). Essendo biodegradabile, 
l’HA può essere vantaggioso rispetto al PEG. L’HA è un polimero endogeno 
ed è metabolizzato dalle ialuronidasi, inoltre ha il vantaggio di poter 
raggiungere una capacità di loading elevate rispetto al PEG, grazie alla 
presenza di gruppi funzionali ripetitivi in ciascun monomero. 
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In questa parte del lavoro di tesi, la ricerca si è concentrata sullo studio della 
coniugazione dell’HA a due enzimi modello, Ribonuclease A e tripsina, e poi 
ad un interessante proteina per uso farmaceutico, l’insulina. 
Per evitare fenomeni di cross-linking, solo una parte dei gruppi carbossilici 
del polimero è stata coniugata ad uno spacer aldeidico, consentendo la 
coniugazione con i gruppi amminici delle proteine. Inoltre, modulando il pH di 
reazione si sono potuti ottenere coniugati con legame selettivo all’N-terminale 
(pH 6) oppure random (pH 8), sfruttando la differente pKa degli ammino 
gruppi nelle proteine. 
I primi coniugati ottenuti con gli enzimi Ribonuclease A e tripsina sono stati 
studiati verificandone l’attività residua rispetto alle proteine native. Tutti i 
coniugati, in particolare quelli ottenuti per legame selettivo all’N-terminale, 
mantengono una buona attività su piccoli substrati (diminuzione del 30%); solo 
il derivato HA-tripsina mantiene circa il 60% di attività residua nei confronti 
del substrato ad alto peso molecolare. Inoltre, sempre per HA-tripsina, si è 
trovata una maggiore stabilità nel tempo rispetto l’enzima nativo (mediamente 
45%) e si è confermata la suscettibilità di entrambe i coniugati nei confronti 
della ialuronidasi. 
La valutazione del polimero come potenziale carrier per proteine è 
proseguita preparando dei coniugati con l’insulina bovina, come esempio di 
proteina farmacologicamente attiva. Sono stati sintetizzati due coniugati con 
modalità selettiva all’N-terminale a partire da polimeri con diverso grado di 
modifica con gruppi aldeidici, pari a 4 e 21% e si sono ottenuti prodotti con il 
17 e 32% (p/p), rispettivamente, di loading proteico. 
L’efficacia terapeutica dei coniugati in comparazione con l’insulina è stata 
testata su ratti Sprague Dawley con diabete indotto. Il coniugato con un minore 
loading proteico si è rivelato essere più efficace e con una riduzione dei livelli 
di glucosio nel sangue più prolungata. 
Nella seconda parte di questo lavoro di tesi si è studiata un’innovativa 
strategia di PEGhilazione enzimatica di sequenze oligonucleotidiche al fine di 
sviluppare questo approccio per il delivery di oligonucleotidi. Il metodo è stato 
messo a punto con sequenze nucleotidiche modello e l’approccio è stato il 
seguente: una breve sequenza oligonucleotica viene legata chimicamente ad 
una catena di PEG. Poi, mediante l’azione catalitica della T4 DNA ligase la 
porzione di PEG-DNA viene coniugata ad un’altra sequenza oligonucleotidica. 
Per lo studio di PEGhilazione enzimatica si è ideato un modello costituito 
da 4 sequenze oligonucleotidiche di riferimento: due coppie complementari 
terminanti con sticky-ends complementari a loro volta (18-mer + 21-mer e 16-
mer + 19-mer). L’oligo di 18 nucleotidi portava in posizione 5’ una funzione 
tiolica, che è stata impiegata per la coniugazione col polimero. 
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Dopo aver apportato alcune variazioni ai protocolli classici di ligazione si 
sono ottenuti ottimi risultati: completa ligazione del modello PEGhilato ed 
assenza di prodotti indesiderati. 
Un’ulteriore conferma di ligazione del modello PEGhilato si è ottenuta 
tramite digestione con EcoRI. Infatti, solamente dopo la ligazione è possibile 
trovare nella sequenza oligonucleotidica il sito di restrizione dell’enzima. In 
presenza o in assenza di polimero la restrizione è avvenuta completamente. 
Si è poi voluto indagare se una sequenza PEGhilata con un numero di basi 
ridotto potesse comunque mantenere i requisiti per essere substrato della T4 
DNA ligase. Così, la coppia di sequenze complementari designata alla 
PEGhilazione è stata ridotta alla meta della sua lunghezza (9-mer + 12-mer). 
Anche con la sequenza PEGhilata così accorciata la ligazione è avvenuta 
completamente. 
In conclusione questo lavoro di tesi ha dimostrato che l’HA può essere una 
promettente alternativa al più noto PEG per la modifica di proteine. 
Nell’ambito del delivery di oligonucleotidi lo sviluppo di un approccio 
enzimatico di coniugazione può aprire nuovi orizzonti in questo settore il cui 
potenziale non è stato ancora esplorato. 
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2.1 DRUG DELIVERY SYSTEMS 
 
Drug delivery systems (DDSs) can be divided into a variety of subjects: 
micro- and nanoparticles, liposomes, matrixes or liquid gels, association with 
cyclodextrines and conjugation with natural or synthetic polymers. These 
systems can be seen as the first generation of “nanomedicines” (Duncan, 
2006). 
Drug delivery systems (DDSs) are particularly promising in improving the 
in vivo efficacy of active molecules. It is possible to prolong the in vivo half-
life and protect the drug from enzymatic degradation, thus enhancing the in 
vivo bioactivity. DDSs can be used either for the delivery of classic low 
molecular weight pharmaceuticals with short PK profile (as anticancer drug) 
but also for biotechnologic products such as proteins and oligonucleotides. 
The drug delivery in conjunction with the controlled drug release can reach 
unprecedented results in many therapeutic fields and can find application also 
in a field like tissue engineering. 
 
 
2.1.1 Tissue Engineering 
 
As a consequence of disease or trauma, the tissues and organs in our bodies 
may be unable to perform their anatomical and metabolic functions. Until 
recently the use of implants, and in severe cases transplants, is the only way to 
deal with these pathological conditions (Terada et al., 2000). In recent years, a 
new branch of regenerative medicine called tissue engineering is under 
development. This term, officially coined in 1988 by the National Science 
Foundation, indicates that this multidisciplinary field produces biological 
substitutes containing living and functional cells for regeneration, maintaining 
or improving performance of the tissue (Langer and Vacanti, 1993). 
Tissue engineering represents the meeting point of different disciplines such 
as medicine, biology, engineering, and chemistry with the common purpose for 
obtaining or replacing organs or parts of organs in the human body. This will 
make possible to have a viable alternative to transplantation, as this can have 
many fundamental problems such as the chronic shortage of donors, the 
phenomena of organ rejection and the continued need to take 
immunosuppressive drugs (Terada et al., 2000). In general, a tissue engineering 
construct is formed by cellular component and a basic structure with function 
support. By production of extracellular matrix, the cells promote the interaction 
with the implantation site. A great advantage of this technique is that the cells 
can be donated from the patient himself; once selected they are grown in vitro 
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and subsequently replanted (Suh, 2000). The basic structure can be by an 
artificial component, polymer type, or from natural component that can ensure 
the support to the cell populations of interest. 
Therefore, the aims of tissue engineering are to design organs and 
prostheses, and to assess the interaction between biomaterial and cellular 
component facilitating the rapid and efficient regeneration of the original 
tissue. Moreover, the support must be biocompatible and biodegradable. To 
optimize the adhesion and cell growth, adhesion peptides are derived from the 
sequence RGD (arginine, glycine, aspartic acid), or the proteoglycan KSRS 
type (lysine, serine, arginine, serine). Another way to allow cell proliferation is 
to add sequences to the culture medium that belong to active growth factors 
specific for the type of cells used. 
When the tissue around the defect has no inherent potential to regenerate, 
the tissue regeneration cannot always be expected by providing the scaffolding 
technology and space mentioned above. In this case, it would be better to 
combine the technology with cells and/or a growth factor, which has the 
potential to accelerate tissue regeneration. It is possible to use cells that were 
proliferated in vitro by the method described above. 
To overcome the problem of the in vivo instability of biological substances 
such as protein and genes that are used to induce tissue regeneration, it is vital 
to use technology to develop the administration form. Indeed, when a solution 
of the growth factor is injected into the site requiring regeneration, the 
biological effect cannot be always predicted. This is because the growth factor 
is rapidly diffused away from the injection site. To enhance the in vivo efficacy 
of the growth factor, the drug delivery system (DDS) is promising. It is 
possible that when used in combination with an appropriate DDS technology, 
the growth factor enhances the in vivo proliferation and differentiation of key 
cells that promotes tissue regeneration. For example, the controlled release of a 
growth factor at the site of action over an extended time period is performed by 
incorporating the factor into an appropriate carrier. It is also possible that the 
growth factor is protected against proteolysis, as it is incorporated in the 
release carrier for prolonged retention of the activity in vivo. DDS technology 
can be also useful for half-life prolongation, absorption improvement and 
targeting, applicable in tissue engineering using protein and genes. 
 
 
2.1.2 Biotech drugs 
 
Biotechnology (or “biotech”) is defined as the use of living systems and 
organisms to develop or make useful products, or “any technological 
application that uses biological systems, living organisms or derivatives 
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thereof, to make or modify products or processes for specific use” (Convention 
on Biological Diversity of UN, 1992). 
Biotech products are mainly represented by proteins, produced thanks to the 
recombinant DNA technology. Their applications involve health, feeding and 
agriculture. 
The advent of recombinant DNA technology has occurred around the 70’s 
and has led to a rapid development of the use of biotech in therapy, in 
particular for proteins. Often named simply “biological”, biotech drugs are 
already widespread in fact, the clinical application of cytokines and other 
biological response modifiers such as thrombolytic agents, adhesion molecules, 
peptide fragments of agonists and antagonists of growth factors and their 
receptors and antibodies. They are commonly required for genetic or chronic 
diseases, where a key role protein is missing, mis-functional or lacking. 
Very close to this kind of products there are also therapeutic 
oligonucleotides. They are not really biotech; in fact they are usually produced 
by synthetic systems. Although the synthetic production, they represent an 
originally natural component of the cell, then they frequently are comprised or 
closely related to “biotech product”. They are prevalently indicated for tumour 
and genetic/rare disorders. It is possible mainly describe two classes for 
therapeutic application: short and long sequences. Short oligomers are possibly 
administered as “classical drugs” and they usually act blocking proteins 
translation (antisense technology and triple helix) or function (aptamers and 
ribozymes). Long sequences are used for gene therapy, the introduction of the 
correct gene sequence in a patient’s genetic code. 
This biotech drugs share common difficulties for widespread use in therapy. 
Firstly, they are fast cleared from the body by the action of reticuloendothelial 
system (RES), kidney excretion or spleen/liver capture. One of the best 
approaches to overcome these inconveniences is the conjugation to polymers, 
an approach following described. 
 
 
2.2 POLYMER THERAPEUTICS 
 
The term “polymer therapeutics” (Duncan et al., 1996; Duncan 1997) 
describes the family of compounds of drug delivery systems that include a 
water-soluble polymer as a common central component (core component) and 
a drug as active ingredient. The term includes polymeric drugs, polymer-drug 
conjugates, polymer-protein conjugates, non-viral vectors and polymeric 
micelles that trap covalently bound drugs (Duncan 2006). 
The compounds obtained with these technologies are “new chemical 
entities” or “pro-drugs”, according to fact that the conjugate is already active or 
that the drug bound needs to be released in order to performed its action. The 
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pro-drug is an inactive compound that is able to release the active drug at the 
site of action where the drug release is triggered by specific conditions in the 
target site. The conjugation of drugs with polymers form the so-called 
“Polymeric pro-drugs” which are part of the category of “Polymeric Drug 
Delivery System (PDDs)” (Jayant and Tamara, 2006). The task of these 
systems is to improve drug distribution, bioavailability, targeting, PK and 
provide a controlled release of therapeutic agent over time. 
 
 
2.2.1 Use of polymers for the controlled release of biological active 
molecules 
 
The delivery of biologically active molecules, especially with various types 
of polymeric systems has several advantages: 
 
 
• increased half life; 
• less frequent administration; 
• increased maximum tolerated dose; 
• protection of the drug from inactivation (Hoes and Feijen, 1989; Pasut 
and Veronese, 2012). 
 
 
Drug release from polymeric systems may be due principally to a physical 
or chemical mechanism: 
 
 
• physically controlled-release: the drug is encapsulated in an insoluble 
polymer membrane or dispersed in a soluble polymer matrix. The drug 
release occurs by diffusion. 
 
• chemically/enzymatically controlled release: the active molecule is 
covalently linked to the polymer by a spacer or a sensible linkage that 
allows the release of the drug only in a specific condition (for example 
acid pH) or thanks to a specific enzyme cleavage (Cavallaro et al., 
2001). 
 
 
The bioactive molecule field has had great developments in bioconjugation, 
which provides the formation of a covalent bond between a polymer and an 
active molecule, creating a new chemical entity that has typical characteristics 
(Cavallaro et al., 2001). 
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2.2.2 Polymeric conjugated 
 
The use of a soluble macromolecular carrier for the delivery of bioactive 
molecules can improve the pharmacokinetic characteristics preserving activity 
and bioavailability. The only characteristics modified are the half-life, its 
distribution in various body compartments and its elimination. 
The use of carrier systems based on synthetic water-soluble polymers, 
defined as polymeric drug carriers, was proposed for the first time in 1975 by 
Helmut Ringsdorf (Ringsdorf, 1975). He suggested to covalently link a drug to 
a water-soluble polymer, through a linker sensitive to enzymatic or hydrolytic 
cleavage at the target site (Figure 2.1). 
 
 
Figure 2.1: Model of polymeric drug carrier suggested by Ringsdorf. 
 
The ideal conjugates should be composed as follow: 
 
• an inert water-soluble polymeric carrier (polymer backbone); 
• a linker between biodegradable polymer and active molecules 
(intracellulary cleavable linker) that is cleaved only at the site of action, 
releasing the active biomolecules; 
• a targeting ligand that can be linked to the polymer structure, promoting 
the selective action of the drug towards the target cells while 
minimizing non-specific interactions; 
• functional additive groups, which influence the solubility of the 
conjugate. 
 
 
2.2.3 Characteristics of polymeric carrier 
 
As mentioned earlier (§ 2.2.2) (Ringsdorf, 1975; Putnam and Kopecek, 
1995), Ringsdorf polymeric carrier model must have certain characteristics. In 
this regards so far several polymers for drug delivery of natural and synthetic 
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origin have been studied. This resulted in the identification of requirements for 
an ideal carrier: 
 
• the polymer must be biocompatible and not induce significant toxicity 
or immunogenicity; 
• must be biodegradable by hydrolytic or enzymatic activity or have a 
molecular weight below the kidney excretion threshold; 
• posses a low polydispersity; 
• the polymer must be found in large-scale, low cost and made by simple 
economic processes; 
• must be hydrophilic to ensure its solubility in body fluids and to 
increase the solubility of the bound drug; 
• must possess the functional groups that allow binding of the drug and 
the residue targeting with simple chemical reactions, not involving 
toxicity or immunogenicity; 
• the linkage between polymer and drug must be sufficiently stable in the 
bloodstream and easily hydrolysable in the target cells, in order to have 
a controlled release of the drug; 
• the conjugate must present a sufficient carrying capacity, to ensure a 
proper amount of drug at the site of action; 
• industrial production of the conjugate must be reproducible, economic 
and its analytical characterization must be complete and validated; 
• the characteristics of the conjugate must be sufficient for an appropriate 
formulation with an high stability and easy administration. 
 
 
2.2.4 Examples of polymer therapeutics 
 
Different types of polymers are used as drug carriers in therapy, both of 
natural origin (dextran, dextrin, polysialic acid (PSA), hyaluronic acid (HA), 
human serum albumin, chitosan and DNA) and synthetic (N-(2-hydroxypropyl) 
methacrylamide copolymer (HPMA), poly-(styrene-co-maleic anhydride) 
(SMA), poly-(vinylpyrrolidone) (PVP), poly-(ethylene glycol) (PEG), poly-(N-
acryloyl) morpholine (PACM), poly-(ethyleneimine) (PEI), poly-(divinyl 
ether-co-maleic anhydride) (DIVEMA)), hydroxy-ethyl-starch and  
polyoxazoline (Putnam and Kopecek, 1995; Maeda et al., 1992; Gregoriadis et 
al., 2005; Besheer et al., 2009; Ferguson et al., 2009; Mero et al., 2008, 2012; 
D’Este et al., 2010; Saravanakumar et al., 2010; Viegas et al., 2011). 
Synthetic polymers are usually preferred to natural ones because they can be 
better tailored following specific characteristics, as controlled molecular 
weight, chemical composition, functionalization with active ingredients, 
targeting residues, biodegradable linkers and solubilizing groups. They are 
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usually less immunogenic than natural polymers especially because natural 
ones are usually extracted from bacteria or other animal species. 
Polymers of natural origin, such as polysaccharides and poly-amino acids, 
are generally biodegradable, because they are hydrolyzed by catabolic 
mechanisms. The biodegradability is one of the main advantages of natural 
polymers, also present in some synthetic polymers, because it prevents any 
phenomenon of accumulation. 
 
 
2.2.5 Bioactive molecules release 
 
The bioactive molecules bound to macromolecular synthetic carrier can be 
release as following: 
 
• passive hydrolysis 
• pH-dependent hydrolysis 
• enzymatic hydrolysis 
 
The step of hydrolysis mainly involves those bonds that are sensitive to 
hydrolytic action, such as esters, and partially amides, carbonates and 
urethanes. The percentage of the released drug will depend on the stability of 
the bonds. This will be greater for the ester groups because they are very 
sensitive to hydrolysis, and decrease progressively with carbonates, urethanes 
and amides. 
The acidic environment of lysosomes (pH of about 4.5-5.5) can be exploited 
to obtain pH dependent hydrolysis by linking of the bioactive molecules to the 
polymer through a linker sensitive to this environment (Shen and Ryser, 1981; 
Cavallaro et al., 2001). Enzymatic hydrolysis may occur in conjugates that 
present a polypeptide or another spacer, between the active molecule and 
carrier, sensitive to the action of one of the many enzymes present in the 
lysosomal level, such as phosphatases, esterases, glycosidases and peptidases 
(Soyez et al., 1996; Duncan et al., 1991). In the literature there are examples of 
conjugates designed to be sensitive to cathepsins, cysteine-dependent peptidase 
present in large quantities and with high activity at lysosomal level. 
 
 
2.2.6 Problems and advantages of bioconjugation 
 
Bioconjugation certainly represents an encouraging strategy for the 
administration of drugs that are characterized by low pharmacokinetic and 
pharmacodynamic profiles. Nevertheless, many issues must be resolved or 
refined to obtain an ideal bioconjugation, especially regarding the polymers: 
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• the chemical activation of the polymer used; 
• a site specific conjugation, in order to prevent the inactivation or the 
activity reduction of the drug; 
• development of analytical methods for a fast conjugate 
characterization (polymer and active residue); 
• the achievement of low polydispersity polymers; 
• the polymer approval for pharmaceutical use by the responsible 
authorities (FDA, EMEA). 
 
Despite these limitations, bioconjugation improves the drug 
pharmacokinetic-pharmacodynamic properties, providing mainly the following 
positive effects: 
 
• masking of antigenic/immunogenic sites of the drug, especially for 
protein; 
• reduced renal excretion, due to the increased hydrodynamic volume; 
• increased plasma half-life (thanks to the previous points); 
• increased solubility of the drug in biological fluids; 
• delivery of the drug to the target tissue (and accumulation) thanks to 
specific targeting residues; 
• less frequent administration and lower doses than the free drug; 
• increased patient compliance and consequent improvement in life 
quality. 
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2.3 HYALURONIC ACID (HA) 
 
 
2.3.1 Chemical-physical characterization and functions 
 
HA is a unique natural glycosaminoglycan, having a relatively simple linear 
structure of repeated non-sulfated disaccharide units composed of D-
glucuronic acid and N-acetyl-D-glucosamine, joined together with alternating 
linkages, β-(14) and β-(13) (Almond, 2007) (Figure 2.2). In addition, 
intramolecular hydrogen bonds stabilize the structure. 
It was initially obtained from rooster combs, while currently is mainly 
obtained by bacterial fermentation. 
 
 
Figure 2.2: Chemical structure of hyaluronan. 
 
At physiological pH, the carboxyl groups of the glucuronic acid residues are 
ionized, conferring to the polymer high solubility in water. In fact, it 
complexes many water molecules, strongly hydrating itself and forming 
solutions with high viscosity. 
Hyaluronic acid is a biological molecule with very important roles in the 
body, essential for cells growth, mobility and differentiation. It is a major 
component of the connective tissue in which it maintains the degree of 
hydration, firmness, plasticity and viscosity of the amorphous matrix and gives 
the skin strength and shape retention. It is the main component of the vitreous 
humor and cartilages, where it has a key structural role in the organization of 
the cartilage extracellular matrix. The size of the molecule and its high 
hydration help the preservation of the shape of tissues. Furthermore, HA has 
other functions, like cementing and anti-shock substance, preventing the 
damage of cells after physical stress and lubricant in synovial fluid. 
In addition, it plays as a physical filter to prevent the spread of bacteria, 
infectious agents, and viruses. 
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2.3.2 HA uses and applications 
 
Hyaluronic acid is widely used in health care. The main uses are for 
surgical, ophthalmic and in the field of cosmetic dermatology (Balazs, 1983; 
Laurent and Frasent, 1992; Laurent, 1998; Ohri et al., 2004; Nakamura, 2006). 
Among the several therapeutic applications, the polymer is currently in clinical 
use in arthritis as a viscosupplement for the joints (Balazs end Denlinger, 
1993). Furthermore, it is widely used in topical formulations for wound healing 
and in several injectable products for cosmetic applications (Muzzarelli et al., 
2012; Palumbo et al., 2012; Laurent and Fraser, 1992; Balazs and Laurent, 
1998). Consequently, its clinical safety is well established. It is also used to 
reduce pain and promote the treatment of inflammation and ulcers, like ulcers 
of the mouth and stomatitis, mainly caused by chemotherapy and radiotherapy. 
In addition to these applications, the potentialities of HA have been 
investigated also in drug delivery as carrier of anti-tumoral and anti-
inflammatory drugs (Banzato et al., 2008; Pitarresi et al., 2010; Saravanakumar 
et al., 2010; Homma et al., 2009). In the last two cases, the presence of several 
carboxylic groups is an advantage for the delivery of small drugs because it 
ensures a high loading. In contrast, as aforementioned, an approach of site 
selective conjugation is needed for protein delivery to avoid cross-linking. 
Some other examples are hydrogels containing erythropoietin (Laurent, 
1998), modified release formulations of human growth hormone (Motokawa, 
2005), paclitaxel and doxorubicin conjugation (Luo et al., 2000; Luo et al., 
2002). In the last years also our lab studied the potential value of this polymer 
in the conjugation of biologically active molecules (HAylation) (D’Este et al., 
2010; Mero et al., 2013). 
 
 
2.4 POLY(ETHYLENE GLYCOL) (PEG) 
 
 
2.4.1 Chemical-physical characterization 
 
Poly(ethylene glycol) (PEG) (Bailey and Koleske, 1976) is a synthetic 
amphiphilic polymer constituted by repeating oxyethylene units with molecular 
weight of 44 Da, and has the following structure: 
 
HO[CH2CH2O]nH  or  CH3O[CH2CH2O]nH 
 
Figure 2.3: Structure of poly(ethylene glycol). 
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Its synthesis is schematically shown in Figure 2.4 and it involves three 
steps: 
 
I. Initiation: it begins with the nucleophile attack of OH- to ethylene oxide 
cyclic opening the epoxy ring and the formation of oxygen reactive 
alcohol; 
II. Propagation: the reaction propagation continues with the addition of 
other ethylene oxide molecules; 
III. Termination: the reaction is stopped by the action of a terminator. 
 
 
Figure 2.4: Synthesis of poly(ethylene glycol). 
 
PEG is a polymer suitable for bioconjugation thanks to many 
characteristics: it is biocompatible, is not toxic and not immunogenic (Dreborg 
and Akerblom, 1990). It is also not charged and has only one or two 
functionals for drugs coupling. It is soluble in both aqueous and organic 
solutions (Powell, 1980; Mutter and Bayer, 1979). Being a non-biodegradable 
polymer, it must be used at molecular weights below 40 kDa to avoid body 
accumulation (Yamaoka et al., 1994). It is also readily commercially available 
and is not too expensive for a wide range of molecular weights and structures. 
All these features have allowed its widespread in the biomedical field, also 
thanks to its Food and Drug Administration (FDA) approval for human use. 
Depending on the initiator used, different PEGylating agents can be 
synthesized. The mono-methoxy PEG (mPEG) mono-functional: is the leading 
polymer for protein conjugation. 
 
 
2.4.2 PEG uses and applications 
 
Polyethylene glycol is used in advanced pharmaceutical technology to 
conjugates principally proteins and chemical drugs. The bioconjugates present 
improved chemical and physical characteristics, such as: 
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 increased plasma half life; 
 reduced renal excretion; 
 reduced hydrolytic and enzymatic degradation;  
 reduced uptake by the reticuloendothelial system (Zalipsky, 1995);  
 increased solubility in water (Delgado et al., 1992); 
 reduced immunogenicity and antigenicity (Dreborg and Akerblom 
1990; Bhadra et al., 2002; Davis, 1992). 
 
PEGylation is a technique that started in the seventies with particularly 
interest on proteins. It began from random amino PEGylations of model 
proteins (Abuchowski et al., 1977; Abuchowski et al., 1997) and presently 
accounts several PEGylated conjugates in clinical practice, some of which are 
blockbuster products (Maggon, 2007; Pasut and Veronese, 2007) (Table 2.1 
and Table 2.2). 
 
PEGylation technique has been widely used also for the delivery of 
anticancer drugs to specifically target the drug to the tumour tissue, preventing 
the distribution to other areas and avoiding side effects. 
Examples of PEG conjugates with anticancer drugs include camptothecin, 
Ara-C, methotrexate and other taxanes. In all cases the aim is to target the 
antineoplastic agent in the tumour tissue, thus reducing systemic toxicity and 
also to increase the water solubility, improving overall the pharmacodynamic 
and pharmacokinetic profiles (Veronese et. al., 2004). 
PEG is also used for the precipitation of proteins and nucleic acids, for the 
synthesis of peptides and oligonucleotides in liquid and solid phase and for the 
enzymatic catalysis in organic solvents. It is also used in cosmetic and pharma 
industry as excipient. 
Recently, it is also widely used by pharmaceutical industry for the 
preparation of drug delivery systems (DDSs) such as liposomes, nanoparticles, 
nano-and microspheres, dendrimers and hydrogels (Bhadra et al., 2002). 
 
 
2.5 PROTEIN THERAPEUTICS 
 
 
2.5.1 Protein drugs 
 
Since the advent of recombinant DNA technology, it was possible to 
produce proteins easily and in large amount. 
In nature, proteins have the most dynamic and diverse roles compared to 
any other macromolecules. In the body, they catalyse biochemical reactions, 
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transduce signals (receptors), provide intracellular and extracellular scaffolding 
support, and transport molecules within a cell or from one organ to another. 
They are estimated to be tens of thousands, each one with possibly different 
role. Mutation or disregulation of the translation can directly cause a disease. 
So, a disease caused by the lack of a protein can be treated with the 
administration of the protein itself. Viewed from the perspective of 
therapeutics, in fact, these represent a tremendous opportunity. 
Presently, the Food and Drug Administration (FDA) has approved more 
than 130 different proteins or peptides for clinical use, and many more are in 
development (Leader et al., 2008). 
Currently, protein drugs are very diversified in terms of production, function 
and origins: some are recombinant human proteins (for instance, insulin, 
growth hormone and erythropoietin), others are monoclonal antibodies (for 
instance, Remicade® (infliximab), Rituxan® (rituximab) and Erbitux® 
(cetuximab)) and still others are viral or bacterial proteins used as vaccines to 
elicit a specific immune response. 
Nature did not evolve proteins for manufacture them ex vivo. For this 
reason, many human proteins produced in recombinant form are difficult to 
manufacture and some cannot be expressed at all in microbial cell culture. 
Furthermore, in human body the serum half-life and tissue distribution of 
endogenously expressed proteins is carefully controlled in vivo to optimize 
their biological activity. Recombinant proteins therefore tend to be rapidly 
cleared and thus require frequent injections (thus, the growing interest in 
extending the serum half-life by, for example, polyethylene glycol conjugation 
or DDSs). 
 
 
2.5.2 Protein conjugation 
 
For the conjugation of proteins, monofunctional or polyfunctional polymers 
have been used (i.e. having one or more reactive functions). 
Especially in the past, dextran has been wudely used, because it’s a 
polyfunctional polymer, uncharged and water-soluble. Many proteins were 
conjugated to dextran, with huge interest: streptokinase, plasmin, asparaginase 
and carboxypeptidase G. Despite the results obtained with these conjugates, 
dextran did not have great success in the derivatization of proteins, because, 
being a multifunctional product, it can give rise to a heterogeneous mixture of 
products and cross-linking problems. 
Another polyfunctional polymer is the copolymer styrene-maleic anhydride 
(SMA), used in the conjugation of neocarcinostatina and superoxide dismutase. 
Homologous polymer is made up of divinyl ether and maleic anhydride 
(DIVEMA). 
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The polyfunctional polymers possess advantages in the enzymatic 
biocatalysis in organic solvent. In this case, the complex pattern that is formed 
by the coupling reaction between polymer and enzymes confer upon them a 
greater stability towards denaturation. 
The cross-linking issue has been overcome by using polymers with a single 
reactive group. For this purpose, one of the more interesting has been 
polyethylene glycol (PEG), which, thanks to its monofunctional group prevents 
the formation of cross-links. Thanks to its characteristics and the possibility of 
obtaining homogeneous protein conjugates, the PEG is the most widely used 
polymer in bioconjugation (Veronese and Morpurgo, 1999). Up today 9 
proteins and a peptide derivatives are commercially available (Table 2.1). 
 
Table 2.1: PEGylated proteins on the market. 
Trade 
name 
Conjugate name Active substance Indication 
Approval 
year 
Omontys® PEGinesatide 
Functional 
analogue of EPO 
Anaemia due to chronic 
kidney disease (CKD) in 
adult patients on dialysis 
2012 
Pegloticase
® 
Krystexxa Uricase Refractory chronic gout 2010 
Cimzia® 
Certolizumab 
pegol 
Anti-TNF Fab’ 
Crohn’s disease and 
rheumatoid arthritis 
2008 
Mircera® PEG-EPO EPO 
Anaemia, causing 
symptoms in adults with 
chronic kidney disease 
2007 
(Europe) 
Somavert® Pegvisomant hGH antagonist Acromegaly 2002 
Neulasta® Pegfilgrastim GCSF Neutropenia 2002 
PEGASYS® Peginterferon-α2a Interferon-α2a 
Chronic hepatitis C, 
hepatitis B 
2001 
PegIntron® Peginterferon-α2b Interferon-α2b Chronic hepatitis C 2000 
Oncaspar® Pegaspargase Asparaginase Leukemia 1994 
Adagen® Pegademase 
Adenosine 
Deaminase 
(bovine) 
Severe combined 
immunodeficiency disease 
(SCID) with a deficiency of 
adenosine deaminase. 
1990 
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2.6 OLIGONUCLEOTIDE THERAPEUTICS 
 
 
2.6.1 Oligonucleotides as drugs 
 
Whole genes or short sequences of oligonucleotides have acquired 
relevance in the pharmaceutical field, mostly because of their selectivity of 
action and because in some cases they are not only a treatment but a definitive 
cure. They are generally chemically synthesized, especially relatively short 
sequences, but it is also possible to extract an entire genome from cells. 
Genes are predominantly used for the treatment of genetic diseases, 
replacing the “wrong sequence” with the “right” and functional one. Short 
oligonucleotides are mostly involved in tumor or monogenic disease treatment. 
Substantially, they act inactivating or inhibiting a protein translation and 
production, usefull when the protein plays a key role in the pathological 
condition. 
According to these actions, single stranded oligonucleotides could be 
principally subdivided in 6 different strategies, explained below. 
 
Antisense technology 
 
Antisense refers to opposing the normal order (“sense”) of the code in 
DNA. Treatment consists in the administration of an RNA sequence, 
complementary to the sequence of mRNA coding for a protein. The formation 
of the double-stranded RNA will prevent the translation of the protein by the 
ribosome. Furthermore the double-strand will be recognized by the enzyme 
RNase H that degrades it (Figure 2.5). 
 
 
Figure 2.5: Antisense technology principle. 
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This strategy can be used to block expression of a gene that could be 
deleterious to the organism because overexpressed or malfunctioning. 
It is possible to treat, for example, the overexpression of oncogenes, of 
cytokines that lead to an inflammatory state and angiotensinogen. 
OBLIMERSEN® recognizes mRNA coding for bcl-2 (antineoplastic 
overexpressed protooncogene in numerous types of cancer), and stimulates 
RNase-H which degrades the RNA restoring the balance between the protein 
pro- and anti-apoptotic (Cheson, 2007). 
To enhance the delivery of RNA, liposomes and polymeric carriers have 
been exploited (Merdan et al., 2002; Ruponen et al., 2003). 
 
Triple-helixes 
 
Some nucleotides are able to complex with DNA in triple-helix forming 
regions that block the transcription and the translation that lead to the protein 
production; RNA polymerase is not able anymore to bind the DNA and 
transcribed it in mRNA. In this case the target is the gene. 
 
Aptamers 
 
It has been found that some nucleotide sequences (single or double strand) 
have the capacity to interact with high affinity to specific proteins, blocking 
their activity. They were called aptamers (from the Latin aptus - fit, and Greek 
meros - region). The best-known example is pegaptanib (Macugen®), product 
currently in the market (Table 3.2), used for the age-related macular 
degeneration of the retina. It is an oligonucleotide that binds Vascular 
Endothelial Growth Factor (VEGF). To improve the pharmacokinetic profile 
changes have been made in position 2’ and 3’ sugar. Moreover, in 5’ has been 
linked by a chain of 40 kDa PEG (§ 2.6.2, Figure 2.6). 
 
Ribozyme 
 
Ribozymes are RNA sequences with catalytic activity able to cleave 
covalent bonds. They can be exploited to degrade the mRNA coding for 
defective or overexpressed proteins. 
 
siRNA 
 
Small interfering RNA (siRNA) is also known as short interfering RNA or 
silencing RNA. It represents a class of double-stranded RNA molecules, 
usually 20-25 base pairs in length. siRNA plays many roles, but its most 
notable is in the RNA interference (RNAi) pathway, where it inhibits the 
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expression of specific genes with complementary nucleotide sequence. siRNA 
also acts in RNAi-related pathways, for example, as an antiviral mechanism or 
in shaping the chromatin structure of a genome. The complexity of these 
pathways is only now being elucidated. 
This mechanism was first discovered in plant, with an important role in 
post-transcriptional gene silencing (PTGS) (Hamilton and Baulcombe, 1999). 
Only at the beginning of this century it was proved that siRNAs could induce 
RNAi in mammalian cells (Elbashir et al., 2001). This discovery led to a great 
interest in harnessing RNAi for biomedical research and drug development. 
 
DECOY 
 
The RNA decoy (commonly known linc-MD1) acts as a protector of the 
mRNA. The decoy RNA protects mRNA from molecules that would stop its 
functions. 
RNA decoys are exogenous molecules that have a sequence matching the 
natural RNA target of an RNA binding protein. Usually the RNA binding 
protein binds to its natural target, but when the RNA decoy is introduced into 
the cell then it binds some of the RNA binding protein. If enough of the decoy 
is in the cell, the RNA binding protein is mostly attached to the decoy and 
some of its natural RNA target is left unbound. This essentially “flips a switch” 
(makes a radical change) in the cell, as the process affected by the RNA 
binding protein-RNA interaction goes from its bound state to its unbound state. 
 
 
The use of DNA or RNA as therapeutic agents, however, shows not 
negligible troubles, for example: 
 
• the presence of enzymes with nuclease activity (non-specific, exo- 
and endonuclease), so the nucleotide sequence is degraded; 
• being polyanions, they can not pass through the membranes because 
of the negative charges and the non-internalisation into the cell 
prevents its translocation to the nucleus; 
• difficulty in targeting the nucleus. 
 
Therefore, it was tried to implement changes in order to limit these 
disadvantages. Initial steps were done increasing the lipophilicity and 
resistance to nucleases. Studies on carriers have been suggested as strategies 
for the transport of these therapeutics to the nucleus. These systems were able 
to protect and improve the transport to the site of action (Merdan et al., 2002; 
Ruponen et al., 2003). 
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2.6.2 Oligonucleotide-polymer conjugation 
 
Oligonucleotides are relatively new molecules in the pharmaceutical field. 
As mentioned in the previous paragraph, interest in them is growing up in the 
last decade. 
Similar to proteins, they are very sensitive substance and only small changes 
on natural environment can destroy or inactivate them. For example, especially 
for RNA handling, sterilized material is needed; otherwise RNase enzymes 
could easily digest all material. 
Conjugation to polymers also in this case can bring the advantages already 
mentioned for the therapeutic use of proteins, such as clearance prolongation 
and reduced enzyme degradation. 
Studies have been conducted for example for LNA (Locked Nucleic Acid) 
antisense oligo. After PEGylation, hybridization is still optimal, circulation 
time and stability are prolonged. Thanks to these improvements lower doses 
are needed respect to the unmodified LNA for the same tumor growth 
inhibition (Bandaru et al., Enzon Pharmaceuticals, inc). 
Other examples are present in literature, especially by Zhao, most of which 
declaring the effectiveness of PEGylation in oligos stability enhancement 
(Zhao et al., 2005; Zhao et al., 2007). 
However, the best-known oligo is Macugen®, a PEG conjugated-
oligonuclotide. The active molecule is Pegaptanib and is marketed by Pfizer 
(FDA N021756, 2004; EMA/671614/2010; EMEA/H/C/000620) (Table 2.2). 
 
Table 2.2: PEGylated oligo on the market. 
Trade name Conjugate name Active substance Indication 
Approval 
year 
Macugen® Pegaptanib anti-VEGF aptamer 
Neovascular (wet) age-
related macular 
degeneration (AMD) 
2004 
 
 
Pegaptanib (Figure 2.6) is a PEGylated modified oligonucleotide that binds 
with high specificity and affinity to extracellular Vascular Endothelial Growth 
Factor (VEGF165) inhibiting its activity (Ng et al., 2006; EMEA 
WC500026218). 
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Figure 2.6: Pegaptanib structure and target binding. a) Sequence and predicted 
secondary structure of pegaptanib. 2’-O-methylated purines are shown in red, 2’-fluorine-
modified pyrimidines are shown in blue and unmodified ribonucleotides are shown in black. 
The site of attachment of a 40-kDa polyethylene glycol moiety is shown. b) Interaction 
between the 55-amino-acid heparin-binding domain of vascular endothelial growth factor 
(VEGF)165 and pegaptanib (Ng et al., 2006). 
 
 

 
 
 
 
 
 
 
 
3 MATERIALS AND 
METHODS 
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 3.1 MATERIALS 
  
Hyaluronic acid sodium salts (HA, 200 kDa) were from Fidia Farmaceutici 
s.p.a. (Abano Terme, Italy). Ribonuclease A, trypsin, bovine insulin, casein 
and testicular hyaluronidase, methanesulfonic acid (CH3SO3H), 1,1’-
carbonyldiimidazole (CDI), 4-aminobutyraldehyde diethyl acetal, sodium 
cyanoborohydride (NaBH3CN), cytidine 2’;3’-cyclic monophosphate 
monosodium salt (CCM), Nα-p-Tosyl-L-arginine methyl ester hydrochloride 
(TAME), triethylamine, ethanolamine, trifluoroacetic acid, copper (II) sulfate 
pentahydrate 4% (w/v), bicinchonicic acid solution, streptozotocin, D2O, 
acetonitrile, ethanol, acetone, glacial acetic acid, hydrochloridric acid (HCl), 
dimethylsulfoxide (DMSO), adenosine triphosphate (ATP), ethanol (EtOH), 
triethylammonium acetate buffer (TEAA), triethylaamine (TEA) and salts of 
analytical grade were from Sigma-Aldrich Co (Taufkirchen, Germany). 
All oligonucleotides were synthesized by Metabion International AG 
(Martinsried, Germany) and Diatech Pharmacogenetics (Jesi, Italy) and stored 
at -20°C in 10 mM Tris-HCl, 1 mM EDTA pH 8.0 (TE). The sequences and 
modifications are: a, 5’-Thio-ACT ATT CCC GGG TAA TGA-3’; aF, 5’-
FAM- ACT ATT CCC GGG TAA TGA -3’; b, 5’-Thio-GGG TAA TGA-3’; 
a', 5’-AAT TCA TTA CCC GGG AAT AGT-3’; b', 5’-AAT TCA TTA CCC-
3’; m, 5’-Pho-ATT CCA AAG CTT CCC CCT A-3’; m', 5’-FAM-T AGG 
GGG AAG CTT TGG-3’ (see Table I.I). PEG Maleimide 20 kDa (mPEG20kDa-
Mal) and ortho-pyridine disulfide PEG 20 kDa (mPEG20kDa-OPSS) were from 
Shearwater Polymers, Inc. (Dallas, Texas, USA). Acrylamide:Bis-acrylamide 
19:1 40% solution was from Merk (Darmstadt, Germany). T4 Polynucleotide 
Kinase (T4 PNK) and Reaction Buffer A were from Fermentas by Thermo 
Scientific (Waltham, MA, USA), T4 DNA Ligase, EcoRI 10U/mL, REact® 3 and 
Sybr Green II from Invitrogen (Life Technologies Ltd, Paisley, UK). 
 
 
 3.2 ANALITICAL METHODS 
 
Spectrophotometer analysis of volumes larger than 0.5 mL was performed 
with a Lambda 25 UV-Vis Perkin-Elmer instrument (Northwolk, CT, USA) 
and for less than 5 µL with a Nanodrop 1000 Spectrophotometer (Thermo 
Scientific, Waltham, MA, USA). 1H-NMR spectroscopy was performed with 
Bruker 300 MHz spectrometer and NMR data were processed using the 
program Topspin (Bruker GmbH, Karlsruhe, Germany). Shimadzu analytical 
HPLC system was used with Zorbax GF-250 (Agilent Technologies, Palo Alto, 
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CA; 4.6 × 250 mm or 9.4 × 250 mm 4 µm) size exclusion chromatography 
(SEC) columns for analytical characterization and purification of HA-
conjugates or with C18 Jupiter (Phenomenex, Torrance, CA, USA; 5 mm, 300 
Å, 250 x 4.60 mm) reverse phase column in association with a TC-50 
temperature controller (Eppendorf, Hamburg, Germany) for characterization 
and purification of PEG-oligo conjugates. Centrifugation was carried out with 
Hettich Zentrifugen mod. MIKRO 200 for small volume and Centrikon T-42K, 
Kontron Company, for large volume solution. The freeze-drying was 
performed with freeze-Hetossic Heto Lab Equipment. The dialysis Amicon® 
Ultra-15 membranes have been provided by Millipore (Billerica, MA, U.S.A.) 
and the dialysis tubing by Del Chimica Scientific Glassware (Naples, Italy). 
DNA acrylamide gels electrophoresis were run with a mini VE vertical 
electrophoresis system (10 x 10.5) by Amersham Biosciences (part of GE 
Healthcare, Glattbrugg, Switzerland). Imaging analysis were performed thanks 
to a Geliance 600 Imaging System in association with GeneSnap software 
(PerkinElmer, Waltham, Massachusetts, USA). Concentration of small 
volumes was performed with a Savant Speed Vac Concentrator (Thermo 
Scientific, Waltham, MA, USA). Aqueous and organic solutions were 
evaporated with Rotavapor mod. R II BÜCHI (Switzerland). Glucose level 
determination was tested by OneTouch® II assay kit (LifeScan Inc, Johnson & 
Johnson, Milpitas, U.S.A.). 
 
 
 3.3 SYNTHESIS AND CARACTHERIZATION OF HA-
PROTEINS 
 
In order to conjugate the polymer to NH2-protein groups, the carboxilic 
residues of the glucuronic acid units were partially derivatizated with an acetal 
ending spacer (4-aminobutyraldehyde diethyl acetal). It will be then 
hydrolyzed into an aldehyde group to couples to proteins forming a reversible 
Shiff base. A secondary amine linkage will be formed after treating with a 
strong reducing agent (NaBH3CN) (see Figure 3.1). 
This method of conjugation also allowed modulating the polymer coupling 
in a random or selective way. In mild basic condition, the NH2 group of lysines 
(pKa ≥ 9.3) on the protein surface are prevalently in the deprotonated form, so 
available for coupling (random approach). Instead, in slightly acid condition, 
only the N-terminal proteins residual are predominantly in deprotonated state 
(thanks to a lower pKa, 7.6-8) generating a selective conjugation. 
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Figure 3.1: General scheme of the bioconjugation strategy of proteins. 
 
 
3.3.1 Synthesis and purification of HA-acetal  
 
HA sodium salt (100 mg, 0.25 mmol) was dissolved in 10 mL of DMSO 
with CH3SO3H (81 µL, 1.25 mmol). After complete dissolution, about 1-2 h, 
1,1’-carbonyldiimidazole (203 mg, 1.25 mmol) was added, followed after 1 h 
by the addition of 4-aminobutyraldehyde diethyl acetal (0.25 mmol) (Figure 
3.2). Triethylamine was used to raise the pH to 8.0. The reaction mixture was 
stirred at 40°C for 12 h and then 1 mL of NaCl saturated solution was added 
drop-wise, till the organic solution became opalescent. After 30 min of mixing, 
the polymer was precipitated slowly by adding 20 mL of chilly ethanol. The 
precipitate was kept at –20°C for 1 hour for a better sedimentation and than 
washed with ethanol/H2O solutions at an increasing percentage of ethanol 
(70:30, 80:20, 90:10, v/v) to remove the excess of water soluble salts and 
reagents (filtering the powder after each step). A better purification of the 
product from unreacted amine was obtained dissolving the dried polymer in 
water and extensively dialysing against demineralized water before 
lyophilization. The derivatization degree was determined by 1H-NMR, 
solubilizing about 4 mg of the powder in 0.75 mL D2O. 
HA-acetal signal in D2O was observed at 1.1 ppm (t, -(OCH2-CH3)2, acetal 
moiety), 1.85 ppm (s, 3H, -NHCO-CH3, HA) and 3.2-3.8 ppm (m, GlcA, 
GlcNAc methylene H, methane-H, HA). 
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Figure 3.2: Scheme of HA-acetal synthesis. Reaction was conducted in DMSO. 
 
 
3.3.2 Synthesis of random HA-RNase A and HA-trypsin (rHA-
RNase A and rHA-trypsin) conjugates 
 
According to the method of bioconjugation to NH2 proteins’ residues, we 
initially synthesized some protein models HA-conjugated. We choose two 
enzymes, RNase A and trypsin, because of the easy way to investigate the 
residual activity of the polymer-linked protein. First of all we obtained the 
random conjugates. 
RNase A and trypsin conjugations were performed using the same 
procedure, as an example the reaction of rHA-RNase A is here reported. HA-
acetal (11 mg, 1.09 µmol; degree of acetal modification 4% mol) was dissolved 
in 3 mL of 25 mM H3PO4 pH 2.1 and stirred for 1 h at 60°C. After cooling to 
room temperature, the pH value of the solution was raised to 8.0 with 0.1 M 
NaOH. RNase A (3 mg, 0.22 µmol), previously dissolved in 1 mL of 0.1 M 
Na2HPO4 buffer pH 8.0, was added. The reaction mixture was diluted to a final 
protein concentration of 0.5 mg/mL with 0.1 M Na2HPO4 buffer pH 8.0. After 
1 h, NaBH3CN (0.69 mg, 10.95 µmol), dissolved in 10 µL of 0.1 M Na2HPO4 
buffer pH 8.0, was added and the reaction was stirred at room temperature for 
48 h. To saturate the still free and reactive aldehydic gruops, 5 equivalent of 
glycine, with respect to each equivalent of aldehyde in the starting HA, were 
added to the reaction mixture. 
The reactions were analyzed by SEC with an analytical Zorbax GF-250 
column (250 × 4.6 mm; 5 µm) eluted with 20 mM Na2HPO4, 130 mM NaCl pH 
7.0, at a flow rate of 0.3 mL/min. The UV-Vis detector was settled at 280 nm. 
The purification was carried out with a semi-preparative GF-250 (250 × 9.4 
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mm) eluted with the same buffer used above at the flow rate of 1 mL/min. The 
purified conjugate was concentrated to 10 mL and the purity was confirmed by 
analytical SEC. The products were extensively dialyzed against demineralized 
water and lyophilized. The total protein content was determined by the average 
of the results obtained by bicinchonicic acid solution colorimetric assay (see 
section 3.3.5) (Smith et al., 1985) and Abs0.1% at 280 nm. 
rHA-trypsin reaction mixture was prepared by using 10.72 mg (1.07 µmol) 
of HA-acetal, 5 mg of trypsin (0.21 µmol) and 0.67 mg of NaBH3CN (10.73 
µmol). The reaction was carried out at 4°C to prevent the autolysis of the 
enzyme. 
 
 
3.3.3 Synthesis of N-terminal HA-RNase A and HA-trypsin (HA-
Nter-RNase A and HA-Nter-trypsin) conjugates 
  
In order to selectively conjugate HA-acetal to the model enzymes at the N-
terminal amino group, the conjugation was carried out as above reported 
except for the pH of the solution of the coupling reaction mixture that was 6.0 
instead of 8.0. The reaction was then stopped and purified as reported above. 
 
 
3.3.4 Synthesis of N-terminal HA-insulin conjugates with different 
grade of loading: HA-Nter-INS 1 and HA-Nter-INS 2 
 
After the results obtained by the HA-enzymes, only the selective 
bioconjugation was following used. Bovine insulin was chosen for coupling to 
HA as an example of protein of strong pharmaceutical interest. This time the 
focus of the observation was the protein loading content, so two conjugates 
were prepared. 
Insulin (INS) was coupled to two HA-acetal derivatives with different 
degrees of activation, 4% and 21% mol, this yielding two conjugates: HA-Nter-
INS 1 and HA-Nter-INS 2, respectively. 
For the preparation of HA-Nter-INS 1, after the hydrolysis of HA-acetal 
(8.81 mg, 0.87 µmol; degree of acetal modification 4% mol) to aldehyde as 
above reported, the pH value of the solution was raised to 6.0 and bovine INS 
(1 mg, 0.17 µmol), dissolved in 0.35 mL of DMSO, was added. After 1 h, 
NaBH3CN (0.11 mg, 174 µmol) was added. 
For the preparation of HA-Nter-INS 2, 1.66 mg of HA-acetal (0.87 µmol; 
degree of acetal modification 21% mol), 1 mg of bovine INS (0.17 µmol) and 
0.11 mg of NaBH3CN (174 µmol) were used. Purification and protein content 
were carried out as reported for the preparation of HA-enzymes. 
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3.3.5 Protein concentration quantification with BCA colorimetric 
method 
 
The amount of each protein conjugate is determined by reading the 
absorbance of the samples at the wavelength of 562 nm, using the method of 
the BCA assay (bicinchoninic acid). It is measured by the colorimetric reaction 
due to the reduction of Cu2+ to Cu1+ in an alkaline medium (the biuret 
reaction), by nitrogen peptide of the protein. Two molecules of BCA chelate a 
cation cuprous turning the solution color from blue-green to purple. The 
intensity of staining is almost linear with respect to protein concentration in a 
range of 20-2000 µg/mL. 
This method was applied because the presence of the polymer should 
interfere in the determination of absorbance at 280 nm, usually used to 
calculate the protein concentration. 
Samples and protein standards (0.2-1 mg/mL) were prepared with a final 
volume of 25 µL. The colorimetric reaction starts after adding to each sample 
twenty volumes (equal to 0.5 mL) of Working Reagent (50 parts of “reagent 
A” and 1 part of “reagent B”, respectively containing bicinchonicic acid 
solution and copper (II) sulfate pentahydrate 4% (w/v)). After an incubation of 
30 min at 37°C the absorbance at 562 nm is evaluated. 
Samples concentrations are obtained from the calibration curve build with 
the standards absorbance values (Abs). 
 
 
3.3.6 Determination of enzymatic activity 
 
HA-enzymes conjugates were characterized on the residual activity respect 
the free protein. Specific substrate were chose: synthetic or protein origin and 
low or high molecular weight (LMWS or HMWS). Two substrates were used 
for the evaluation of trypsin activity: i) casein, a high molecular weight 
substrate for the determination of proteolytic activity and ii) Nα-p-tosyl-L-
arginine methyl ester hydrochloride (TAME·HCl), a low molecular weight 
substrate for the determination of esterase activity. 
 
3.3.6.1 Enzymatic assay for RNase A: hydrolysis of cytidine 2’;3’-
cyclic monophosphate (LMWS) 
 
Free or HA conjugated RNase A samples (100 µL at 0.1 mg/mL protein 
concentration) were added to 1 mL of 0.15 mg/mL of CCM solution (0.46 
mM) dissolved in 0.1 M Tris/acetate buffer pH 7.0. The hydrolysis of the 
substrate was evaluated by measuring the increase of absorbance at 247 nm for 
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5 min. The enzymatic activity was obtained by software elaboration end the 
final result was an averaged between three experiments. 
 
3.3.6.2 Enzymatic assay for trypsin: proteolysis of casein (HMWS) 
 
The hydrolysis rate of casein (MW 26000 Da) was evaluated by 
determining the absorbance of the digested peptides in solution after acid 
protein precipitation, according to Zwilling and Neurath (1981). 
Briefly, in 2 mL test tubes, 500 µL of 0.1 M Tris/HCl pH 8.0 and 400 µL of 
1% casein solution (dissolved in the same buffer) were added. To this solution 
100 µL of free or HA conjugated trypsin samples (40 to 100 µg/mL protein 
concentration) were added. After 15 min at 30°C, 500 µL of a 5% 
trichloroacetic acid solution were added. The precipitate was pelleted by 
centrifugation at 5000 × g for 5 min. The absorbance of the supernatant was 
determined at 280 nm. The enzymatic activity was averaged between three 
experiments. 
 
3.3.6.4 Enzymatic assay for trypsin: esterase hydrolysis of Nα-p-tosyl-
L-arginine methyl ester (LMWS) 
 
Nα-p-tosyl-L-arginine methyl ester hydrochloride (TAME·HCl), was used as 
low molecular weight substrate for the determination of esterase activity of 
trypsin. In this case, the method proposed by Hummel (1959) was used. 
Breafly, in 2 mL test tubes, 500 µL of 40 mM Tris, 10 mM CaCl2, pH 8.1 
and 500 µL of 1.04 mM TAME·HCl solution, in the same buffer, were added. 
The hydrolysis of the substrate was evaluated by monitoring the absorbance at 
247 nm over 5 min after the addition of 50 µL of free or HA conjugated trypsin 
samples (0.1 mg/mL protein concentration). The enzymatic activity was 
obtained by software elaboration end the final result was an averaged between 
three experiments. 
 
 
3.3.7 Thermal stability of HA-conjugates 
 
For the determination of thermal stability, RNase A, trypsin, HA-Nter-RNase 
A and HA-Nter-trypsin were separately incubated for 24 h at 37°C in PBS 
solution. At time 0, 6 h and 24 h of incubation, the necessary volumes of each 
solution were withdrawn to measure the residual enzymatic activity as above 
reported.  
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3.3.8 Digestion of HA-Nter-RNase A and HA-Nter-trypsin conjugates 
by hyaluronidase 
 
Hyaluronidase from bovine testes was added to a solution of HA-protein 
conjugate at 0.1 mg/mL (protein concentration) in 0.1 M Na2HPO4 buffer pH 7 
at the enzyme/HA molar ratio of 1/25 (w/w). The solution was incubated for 24 
h at 37°C. At predetermined time points, a sample of 20 µL was analyzed by 
SEC under the same conditions reported above. 
 
 
3.3.9 Erythrocyte compatibility study 
 
One milliliter of freshly collected heparinized rat blood was centrifuged at 
4000 × g for 10 min. The precipitated erythrocytes were washed three times 
with PBS buffer. The red blood cells (RBCs) were resuspended in PBS buffer 
and diluted to have an optical density in the 0.6–0.7 range at 670 nm. This 
stock erythrocyte suspension was freshly prepared and used within 48 h. For 
the compatibility experiment, 300 µL of the stock suspension were added to 
300 µL of PBS containing HA-Nter-INS 1 or HA-Nter-INS 2 at protein 
concentrations ranging from 0.5 to 3 mg/mL. The samples were incubated at 
37°C for 60 min under constant shaking. After centrifugation at 4000 × g for 
10 min, the released hemoglobin was determined by measuring the absorbance 
at 414 nm. The experiment was performed also with HA sodium salts, using a 
polymer concentration range comparable to the HA content in the experiment 
with HA-Nter-INS conjugates. Complete hemolysis, used as a positive control, 
was achieved by using a 1% v/v solution of Triton X-100 in water, a surfactant 
known to lyse RBCs. The RBC-PBS solution was used as the negative control. 
The percentage RBC lyses was calculated according the following formula:  
 
% lysis = [(Asample – Ablank) / (A100%lysis – Ablank)] × 100 
 
where Asample is the absorbance value of the hemoglobin released from the 
RBCs treated with the polymer or the conjugate solution; Ablank is the 
absorbance value of the hemoglobin released from the RBCs treated with PBS 
buffer; and A100%lysis is the absorbance value of the hemoglobin released from 
RBCs treated with 1% Triton X-100. 
 
 
3.3.10 Ethics statement 
 
All animal procedures were approved by the Ethic Committee of the 
University of Padua and the Italian Health Ministry, and all animals received 
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care according to the DLGS 116/92 and in compliance with the “Guide for the 
Care and Use of Laboratory Animals”. 
 
 
3.3.11 Hypoglycemic potency of HA-Nter-INS 1 and HA-Nter-INS 2 in 
rats 
 
Type I diabetes was induced in rats with streptozotocin (Junod et al., 1967; 
Akbarzadeh et al., 2007). Fifteen adult Sprague-Dawley male rats (250-300 
grams, 75-90 days old) received a dose of 60 mg/kg of streptozotocin in 10 
mM citrate, 0.15 M NaCl, pH 4.5 by intraperitoneal injection (i.p.). Diabetes 
was induced in 12 animals within 3 days, owing to beta cells destruction. 
Animals were randomly divided in four groups and injected subcutaneously 
with insulin, HA-Nter-INS 1, HA-Nter-INS 2 (0.135 units per rats) or PBS. At 
predetermined interval time points glucose levels (mg/dL) in blood samples 
were measured using a OneTouch® II assay kit. 
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3.4 PREPARATION OF PEGYLATED OLIGOS BY 
ENZYMATIC PEGYLATION 
 
In this section it was investigated the capacity of a DNA specific enzyme to 
act on a sequence when is linked to a polymer chain, especially for DNA ligase 
and exploit this method as a new enzymatic mediated PEGylation for 
oligomers. 
 
 
3.4.1 Phosphorilation of a' 
 
Chemically synthesized nucleic acids, if not opportunely modified, are not 
phosphorylated at their ends. Phosphorylation of 5’-ends is strictly required for 
enzymatic ligation of nucleic acids, as in our case ligases need a 5’-phosphate 
and a 3’-OH to link two oligonucleotides to form the phosphodiester bond. 
 
3.4.1.1 5’-OH a' phosphorilation 
 
The m oligonucleotide, was already 5’-P modified (see Table I.I), whereas 
a' was enzymatically phosphorylated using T4 PNK that catalyzes the transfer 
of the γ-phosphate from ATP to the 5’-OH group of oligonucleotides (forward 
reaction). 
20U of T4 PNK were added to a' (1 nmol) in the presence of Reaction 
Buffer A (50 mM Tris-HCl, 10 mM MgCl2, 5 mM DTT, 0.1 mM spermidine, 
pH 7.6) and ATP (10 nmol), in a total volume of 50 µL, at 37°C for 1 hour. 
Posphorilated a' was than recovered by precipitation. 
 
 
3.4.1.2 Oligos precipitation 
 
To obtain clean DNA after enzymatic reactions and reduction, unwanted 
protein residues and buffers were removed by precipitation. 
Briefly, DNA solutions were added of 1/10 of the volume of 3 M sodium 
acetate pH 5.2 and of 3 volumes of cold 100% EtOH. The solution was then 
placed at –80°C for 15 min and centrifuged at 14000 rpm for 20 minutes at 4°C. 
EtOH was removed and the DNA pellet rinsed once with 70% EtOH. The 
washed pellets were centrifuged again for 10 min at 14000 rpm at 4°C. The 
EtOH was definitively removed and the pellets dried in a speed vacuum. After 
drying, pellets were re-suspended in 9/10 of the original volume. 
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3.4.2 Conjugation of PEG to DNA oligos 
 
PEGylation was performed in two different fashions, obtaining a stable or a 
reducible linkage. 
 
3.4.2.1 Synthesis of PEG-a and PEG-b 
 
To synthesize PEG-a and PEG-b, 2 nmol of a and b respectively were 
mixed to a mild excess of mPEG20kDa-Mal (molar ratio of oligo to PEG is 
1:1.2) in 0.1 M H2NaPO4, 2 mM EDTA, pH 7.0 for 30 minutes at room 
temperature. The conjugation reaction was monitored by RP-HPLC and than 
the pegylated oligo was purified. 
 
 
Figure 3.3: Scheme of mPEG-oligo synthesis. 
 
Analysis and purification of PEG-oligos were performed with a C18 Jupiter 
(Phenomenex, USA; 5 µm, 300 Å, 250 x 4.60 mm), eluting at 1 mL/min with a 
gradient (reported below). Eluent A was 0.1 M triethylammonium acetate 
buffer (TEAA), pH 7.0 and ACN was the eluent B (50°C). 
 
time (min) 0 25 27 29 
% ACN 10 50 90 10 
 
Conjugates were collected, dried and re-suspended in MilliQ water. The 
accurate contents of purified conjugates were evaluated by the individual molar 
extinction coefficients after UV-vis spectra analysis, using a nanodrop 
spectrophotometer. 
 
3.4.2.2 Synthesis of PEG-ss-a 
 
PEG-SS-a was prepared in the same condition used for PEG-a and PEG-b, 
excepting for the used polymer, mPEG20kDa-OPSS, and the oligo polymer 
molar ratio (1:5). Purification was carried out after 24 h. 
 
 
Figure 3.4: Scheme of mPEG-ss-oligo synthesis. 
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3.4.3 Annealing 
 
Prior to ligation, the two ds DNA portions were formed. Many methods can 
be used to anneal complementary strands of nucleic acids. In each case, the 
goal is to denature the complementary strands to remove any secondary 
structure and then allow the strands to hybridize. Two factors that influence the 
efficiency of oligonucleotide hybridization are salt concentration and the rate 
of temperature decrease. Annealing occurs most efficiently when the 
temperature is slowly decreased after denaturation, especially when the 
oligonucleotides have high GC content or form hairpin structures. 
 
3.4.3.1 “Classic” annealing 
 
In the “classic” annealing procedure equal amounts of the top and bottom 
strand oligos to generate the ds portions of oligos were annealed (for example 
aF and a' for AF, m and m' for MF). 
We perform the annealing at a final oligo concentration of 50 µM, 
denaturing at 95°C for 5 min and the samples were slowly cool to room 
temperature. 0.25 nmol of each oligo portion (AF and/or MF) were combined 
before the ligase reaction. 
 
 
3.4.3.2 Annealing + “slow step” 
 
This kind of annealing consists in the same procedure explained for 
“classic” annealing with an adding time of 5 h at RT in which the annealed 
portions were already mixed up before the ligation. A prolonged time of 
incubation favours the correct overlap of the sticky-ends. 
 
 
3.4.3.3 “Mix it all” annealing 
 
In “mix it all” procedure annealing the four single-stranded oligos (each 
ones in a final concentration of 25 µM) were mixed together and proceeded to 
anneal before the ligation. Also in this case annealing was done by denaturing 
at 95°C for 5 min and slowly cooling to room temperature. 
 
 
3.4.4 AFMF ligation 
 
According with the three annealing procedure previously describe (§ 3.4.3) 
ligation was performed as reported in Table 3.1. 
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Table 3.1: Different types of matching and pre-ligation procedure. 
 PORTION I PORTION II PROCEDURE 
i AF MF “classic” annealing 
ii AF MF annealing + “slow step” 
iii AF MF “mix it all” annealing 
iv AF AF annealing 
v MF MF annealing 
 
If not already mixed together, after the annealing procedure 0.25 nmol of 
each oligo portion (AF and/or MF) were combined and than ligase buffer 
(50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 1 mM DTT, 5% w/v PEG8kDa) 
and 4U of T4 DNA ligase were added, resulting in 6.25 mM ligated ds-DNA 
concentration (AFMF, or AF2 or MF2). The reaction were maintained at 16°C 
o.n. and controlled by gel-electrophoresis (§ 3.4.11). 
 
 
3.4.5 PEG-AMF ligation 
 
Briefly, after the annealing + “slow step” procedure (§ 3.4.3.2)., 0.25 nmol 
of PEG-A and MF were added of ligase buffer and DNA ligase, resulting in 
6.25 mM ligated ds-DNA concentration. The reactions were maintained at 
16°C o.n. and controlled by gel-electrophoresis (§ 3.4.11). 
 
 
3.4.6 PEG-AMF ligation optimization 
 
We monitored PEG-AMF formation (§ 3.4.5) during time (10 min, 20 min, 
30 min, 1 h, 2 h, 3 h) at three different temperatures: 10°C, 16°C and 21°C. At 
each time a small volume was withdrawn and the enzymatic reaction stopped 
with 25 mM EDTA and freezing. 
The reactions were resolved in a vertical DNA PAGE (§ 3.4.11) and by RP-
HPLC. DNA and fluorescein-modified components were analyzed at 260 and 
494 nm respectively at the same conditions explained at § 3.4.2. In this case 
RP-HPLC elution was done in standard condition (RT), limiting the partial 
destabilization of the double-stranded caused by the high pressure. 
 
 
3.4.7 PEG-ss-AMF ligation 
 
As already reported for PEG-AMF (§ 3.4.5 and 3.4.6), improvements in 
annealing procedure, time and temperature were applied, resulting in a ligation 
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reaction conduct at 21°C for 1 h. All parameters were the same, except for T4 
DNA ligase buffer was DTT-free, to prevent the reduction of the disulfide 
bond between polymer and oligo. 
 
 
3.4.8 PEG-BMF ligation 
 
PEGylation and ligation were developed as described above for PEG-AMF 
in § 3.4.5 and 3.4.6. Results were also evaluated by DNA PAGE (§ 3.4.11). 
 
 
3.4.9 PEG-ss-AMF reduction 
 
After ligation, a part of PEG-SS-AMF was reduced in 0.1 M DTT, pH 7.0 
for 3 h, to form AMF. DNA material was washed from the buffers and excess 
PEG by precipitation as described in § 3.4.1.2. 
 
 
3.4.10 EcoRI restriction 
 
The ligation results were confirmed by EcoRI restriction, in fact only the 
ligated oligos present the exact sequence recognized by the enzyme 
(GAATTC). 
42 pmol of AMF (obtained after reduction treatment of PEG-SS-AMF), 
AFMF or PEG-SS-AMF were mixed with 20U of EcoRI and REact® 3 buffer (5 
mM Tris-HCl pH 8.0, 1 mM MgCl2, 10 mM NaCl). After 1h at 37°C samples 
and references were run in native DNA acrylamide gel electrophoresis (§ 
3.4.11). 
 
3.4.11 Native and denaturing polyacrylamide gel electrophoresis 
 
Ligation and restriction product were resolved in native and/or denaturing (7 
M urea) DNA polyacrylamide gel electrophoresis (PAGE) gels, prepared with 
20% acrylamide in 1 X TBE buffer (89 mM Tris base, 89 mM boric acid, 20 
mM EDTA, pH 8.0). Each well was fill with 10 µL of 2.5 µM oligo solution, 
previously added of loading buffer (containing glycerol as thickener, 
bromophenol blue and xylene cyanol as tracer). 
Separations were run applying 150 V for 3h in a 1 X TBE bath. Gels were 
exposed to a fluorescent lamp to immortalized fluorescein signal, to Sybr 
Green II reagent to detect all the single-stranded sequences and, at the end, to 
ethidium bromide for double-stranded ones. Imagines were saved and analyzed 
with GeneSnap. 
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 4.1 SYNTHESIS AND CHARACTERIZATION OF HA-
PROTEINS 
 
 
 4.1.1 Synthesis and characterization of HA-acetal 
 
In this study, the aldehyde groups were grafted on the HA backbone by 
exploiting a new strategy that allowed the preservation of HA backbone 
(oppositely to the widely used procedure of polysaccharide backbone oxidation 
with periodate). In this case, desired degree of aldehyde modification were 
achieved by coupling few HA carboxylic groups with 4-aminobutyraldehyde 
diethyl acetal. It will be then hydrolyzed into an aldehyde group useful for 
proteins coupling. Within this strategy a Shiff base will be first formed, then 
reduced to secondary amine treating with a reducing agent, NaBH3CN (see 
Figure 3.1). 
A proper acetal derivatization was obtained carrying out the reaction in 
DMSO using the conditions reported in materials and methods. Even if the 
sodium salt of HA is only partially soluble in this solvent, the addition of 
CH3SO3H allowed a complete dissolution of the polymer within 1-2 hours. 
HA-acetal was prepared at two different degrees of derivatization. In both 
cases the recovery were around 80%. The exact degree of modification was 
calculated by 1H-NMR spectroscopy. The comparison of the integral value of 
the acetal group peak (1.10 ppm) with the integral value of HA acetyl group 
peak (1.85 ppm) demonstrated that the two polymer batches were activated at 4 
and 21% mol (Figure 4.1). 
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δH (ppm) Multiplicity Assignment 
4.65 s 2 H, H2O 
3.2-3.8 m 
GlcA, GlcNAc methylene 
H, methane-H 
1.85 s 3 H, -NHCOCH3 
1.10 t 6 H, -CH(OCH2CH3)2 
Figure 4.1: Structure and characterization of HA-acetal derivative. A) Chemical 
structure of HA-acetal derivative. B) 1H-NMR spectroscopy of an HA-acetal derivative in 
D2O: 1.10 ppm, t, (6H, -CH(OCH2-CH3)2, 4-aminobutyraldehyde diethyl acetal), 1.85 ppm, s, 
(3H, -NHCO-CH3, HA), 3.2-3.8 ppm, m (GlcA, GlcNAc methylene H, methane-H, HA). 
 
 
 4.1.2 Synthesis and characterization of HA-enzyme conjugates 
 
Acetal groups of the HA derivative were hydrolyzed to aldehyde groups by 
a mild acid treatment. The hyaluronan-aldehyde derivative was conjugated to 
model enzymes at two pH values, 8.0 for random coupling at the level of 
amino group of lysines and 6.0 for selective protein N-terminus coupling. 
Random conjugation was performed for an indirect evaluation of the steric 
hindrance and the flexibility of HA on the protein surface. 
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The conjugation reactions were monitored by SEC. In Figure 4.2 (panel A), 
it is reported as an example the time course of the conjugation of HA-Nter-
trypsin. The disappearance over the time of the peak of free trypsin (tR= 10.5 
min) corresponded to the appearance of a new peak (tR= 6.13 min), in 
agreement with the formation of HA-Nter-trypsin conjugate that has a higher 
hydrodynamic volume. 
All the purified conjugate were investigated by SEC to ensure the 
elimination of unreacted enzyme (example for HA-Nter-trypsin in Figure 4.2, 
panel B). The purification was considered satisfactory when the peak of the 
starting protein (tR around 10 min) had disappeared or was lower than 1%. 
Protein contents in the conjugates, shown in Tables 4.1 and 4.2, were averaged 
from very similar data obtained by bicinchonicic acid solution assay and 
absorbance at 280 nm on the basis of protein molar extinction. It was verified 
that HA did not affected both determinations. 
 
 
Figure 4.2: Example of conjugation of HA-acetal to trypsin. A) Conjugation reaction of 
HA-Nter-trypsin at times of 0, 6, 21 and 48 h. B) Elution profiles of HA-Nter-trypsin conjugate 
after purification. The low peak eluting at 10-12 min is not referred to free trypsin but it is due 
to the Tris buffer used to dissolve the sample as shown in the elution profile of buffer used as 
control. The analyses were carried out with size exclusion chromatography accordingly to the 
conditions reported in Materials and Methods section. 
 
 
4.1.2.1 Measurements of HA-RNase A activity 
 
The determination of RNase A activity in the corresponding conjugates, 
with the low molecular weight substrate, CCM, displayed a high enzymatic 
activity retention (Table 4.1). As expected, rHA-RNase A had a lower activity 
with respect to HA-Nter-RNase A. This difference is probably due to the 
polymer chains that are a steric obstacle for the substrate recognition with the 
active site, an effect becoming more evident with the increase of the number of 
HA chains coupled per protein unit. 
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LOD = 0.01mg/mL 
 
 
4.1.2.2 Measurements of HA-RNase A thermal stability 
 
The thermal stability investigation, evaluated by monitoring the residual 
enzymatic activity over time at 37°C, showed that both RNase A and HA-Nter-
RNase A retained well the enzymatic activity by losing only 10% of the initial 
activity after 24 h of incubation (Figure 4.3). 
 
Figure 4.3: RNase A and HA-Nter-RNase A thermal stability. Residual activity against 
CCM after 0, 6 and 24 h of incubation in Tris/acetate buffer pH 7.0. Results are presented as 
mean ± s.e.m. (n=3). 
 
 
4.1.2.3 Measurements of HA-trypsin activity 
 
The residual activities of rHA-trypsin and HA-Nter-trypsin have been 
evaluated on low and high molecular weight substrates, TAME·HCl and 
casein, respectively. As expected, also in these cases the two conjugates 
Table 4.1: Properties of HA-RNase A conjugates. 
Sample 
Protein 
content 
(% w/w) 
Free 
Protein 
(%) 
Yield of 
reaction 
(% w/w) 
Activity 
(%) 
RNase A 100  - 100 
rHA-RNase A 21.4 < LOD 33.5 70.3 ± 3.05 
HA-Nter-RNase A 21.2 < LOD 48.5 82.9 ± 2.74 
RNase A 
 
HA-Nter-RNase A 
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showed slightly different enzymatic activities on the basis of the method of 
coupling. The residual proteolytic activity on casein of rHA-trypsin and HA-
Nter-trypsin were reduced at 53% and 61%, while both conjugates displayed a 
better retention of esterolytic activity, 72% and 86%, respectively (Table 4.2). 
These results indicate that the polymer does not completely hinder the 
approach of even large substrates to the catalytic site, probably thanks to its 
backbone flexibility and hydrophilicity. 
 
LOD = 0.01mg/mL 
aLMWS: activity evaluated against Low Molecular Weight Substrate 
bHMWS: activity evaluated against High Molecular Weight Substrate 
 
 
4.1.2.4 Measurements of HA-trypsin thermal stability 
 
In the case of HA-Nter-trypsin and trypsin, the residual activity over the time 
during incubation at 37°C decreased faster than for RNase A. Trypsin was 
quickly inactivated, showing 20% of residual esterolytic activity and 10% of 
proteolytic activity after just 6 h. The decrease of enzymatic activity for the 
conjugate over the time was slower than for free trypsin, as shown by the 
results after 6 h of incubation. In particular, the esterolytic and proteolytic 
activities were 59% and 34%, respectively, of that of trypsin at time zero 
(Figure 4.4, A and B). This demonstrates HAylation markedly increased 
enzyme stability reducing the typical autolysis process, an effect seen also after 
trypsin conjugation with other polymers (Gaertner and Puigserver, 1992). 
 
Table 4.2: Properties of HA-trypsin conjugates 
Sample 
Protein 
content 
(% w/w) 
Free Protein  
(%) 
Yield of 
reaction 
(% w/w) 
Activity 
(%) 
100 (LMWS)a 
trypsin 100 
 
- 
100 (HMWS)b 
72.0 ± 2.74 
(LMWS)a 
rHA-trypsin 8.9 <LOD 21.4 
53.0 ± 6.46 
(HMWS)b 
85.6 ± 4.34 
(LMWS)a 
HA-Nter-trypsin 14.8 <LOD 41.4 
61.3 ± 6.10 
(HMWS)b 
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A B 
A 
 
Figure 4.4: Trypsin and HA-Nter-trypsin thermal stability. A) Residual activity against 
TAME (esterolysis) and B) casein (proteolysis) after 0, 6 and 24 h of incubation in Tris buffer. 
Results are presented as mean ± s.e.m. (n=3-5). 
 
 
4.1.2.3 Treatment of HA-Nter-RNase A and HA-Nter-trypsin by 
hyaluronidase 
 
HA is a biodegradable polymer and this represents a relevant advantage 
over the most used polymer in this field, PEG, which is not biodegradable 
(Pasut et al., 2008). It was therefore important to verify if hyaluronidase, the 
enzyme involved in HA degradation in vivo, was still able to degrade HA after 
its conjugation to a protein The SEC analysis showed that the conjugates’ 
molecular weight was reduced in a time depended manner. In fact, the 
conjugates were eluted as a main peak at 6 min. After incubation with 
hyaluronidase, these peaks disappeared and new peaks with higher retention 
times, and consequently smaller molecular weights appeared over time (Figure 
4.5). 
 
 
Figure 4.5: HA-enzymes degradation by hyaluronidase. A) HA-Nter-RNase A, B) HA-
Nter-trypsin (t=0, 6 and 24h). The SEC elution conditions are reported in Materials and 
Methods section. 
trypsin 
 
HA-Nter-trypsin 
trypsin 
 
HA-Nter-trypsin 
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 4.1.3 Synthesis and characterization of HA-Insulin (HA-INS) 
conjugates 
 
After testing and optimizing the conjugation of HA to model enzymes, the 
HA-acetal derivative was used to prepare a potential therapeutic conjugate with 
insulin. In this case two HA-acetal batches, differing in the degree of acetal 
substitution (4 and 21%), were used to also investigate the effect of protein 
loading.  
The SEC elution profiles of purified products showed a main peak 
corresponding to the conjugates without the presence of detectable amounts of 
free insulin (Figure 4.6). As reported in Table 4.3, the percentages of aldehyde 
groups in the HA backbone correlates, although not proportionally, with the 
insulin loading in the final conjugates, 17.2% and 32% (w/w) for HA-Nter-INS 
1 and HA-Nter-INS 2, respectively, thus suggesting a steric hindrance between 
the polypeptide chains. 
 
 
 
Figure 4.6: Elution profiles of purified HA-INS conjugates in size exclusion 
chromatography. The elution conditions are reported in Materials and Methods section. 
 
Table 4.3: Properties of HA-INS conjugates 
 
LOD = 0.01mg/mL 
 
Sample 
Protein content 
(% w/w) 
Free protein 
(%) 
Yield of reaction 
(% w/w) 
HA-Nter-INS 1 17.2 <LOD 9.6 
HA-Nter-INS 2 32.0 <LOD 18.0 
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4.1.3.1 Erythrocyte compatibility study 
 
Before testing the activity of HA-INS conjugates in vivo, the effect of the 
polymer and HA-INS conjugates on the integrity of the erythrocyte membrane 
was investigated to evaluate the blood compatibility of the compounds. 
The percent of cell lysis, as reported in Figure 4.7, showed that both 
conjugates were non-hemolytic at the concentration used for the in vivo study. 
 
 
Figure 4.1: Haemolytic effect of HA and HA-INS conjugates on mouse red blood cells. 
Results are presented as % of hemoglobin release produced by the different compounds ± S.D. 
(n = 3). Due to similar values, some symbols overlap. 
 
A partial lysis was only shown by HA-Nter-INS 2 (< 20% lysis) but it was 
for a concentration 100 times higher than that used with the animals. 
The starting HA and the insulin conjugate prepared with the HA-acetal at 
4% activation degree showed negligible hemolytic activities. 
 
 
4.1.3.2 In vivo evaluation of HA-INS activity 
 
In order to study in vivo the residual activity of HA-INS conjugates, their 
glucose lowering effect was tested in rats. Type I diabetes was induced with 
streptozotocin in Sprague-Dawley rats, showing after the treatment an average 
basal blood glucose titer of > 200 mg/dL compared to 60-70 mg/dL in normal 
rats. 
To each diabetic rat group was subcutaneously administered a single bolus 
of HA-Nter-INS 1, HA-Nter-INS 2, insulin or PBS (control). The glucose blood 
level for all groups was monitored over time and up to 24 h. The insulin equiv. 
dose was 0.135 IU per animal to avoid more severe hypoglycemic events, 
observed at higher doses. 
HA-Nter-INS 1 
HA-Nter-INS 2 
HA 
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The experimental results are shown in Figure 4.8. The lowering effect on 
glucose blood level of insulin was observed at 1 h post-injection, but the 
glucose titer returned already to the initial value after 2 h. Interestingly, HA-
Nter-INS 1 showed a slower but prolonged onset of the lowering effect, in fact 
the glucose titer reached the minimum concentration at 6 h and then 
progressively returned to the initial value. The prolonged activity of HA-Nter-
INS 1 can be due to a combination of the increased molecular weight of the 
conjugate and the prolonged release of conjugate fractions at a lower molecular 
weight from the site of injection, by the action of hyaluronidase. 
 
 
Figure 4.8: Blood glucose levels in streptozocin-induced diabetic Sprague-Dawley rats. 
Injection of bovine insulin, HA-Nter-INS 1, HA- Nter-INS 2. Results are presented as mean ± 
s.e.m. (n=3-5). Significance: * = p < 0.05 vs insulin. 
Unexpectedly, HA-Nter-INS 2 showed no significant effect on glucose titer. 
Probably the higher insulin loading of HA-Nter-INS 2 led to a steric 
entanglement affecting the receptor/protein recognition. 
INS 
HA-Nter-INS 1 
HA-Nter-INS 2 
* 
* 
* 
* 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 4.2 PREPARATION OF PEGYLATED OLIGOS BY 
ENZYMATIC PEGYLATION 
 
 
In this section of the work an innovative enzyme-mediated oligo 
PEGylation was studied. The method is composed of two steps. The first is a 
chemical PEGylation of a short oligomer; the second is the enzymatic ligation 
of the oligo-PEG with another oligo sequences, catalyzed by T4 DNA ligase. 
In order to investigate the feasibility of this enzyme-mediated oligo 
PEGylation, a model of four DNA sequences was studied. A simple scheme is 
shown in Figure 4.9. 
 
 
Figure 4.9: Scheme of the model ligase reaction. 
 
 
4.2.1 Synthesis of PEGylated oligos 
 
The two 5’-Thiol modified oligos, a and b, were conjugated to mPEG20kDa-
Mal exploiting the Michael addition. 
The yield of conjugation in RP-HLPC analysis was about 93%. To remove 
unreacted PEG and oligo, the conjugates were purified by RP-HPLC (example 
in Figure 4.10), obtaining PEG-a and PEG-b for each conjugation reactions. 
a' m' 
 
 
A MF 
 
 
a 
 
 
m 
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PEG-SS-a was synthesized by coupling the thiol of a with mPEG20kDa-
OPSS, thus forming a disulfide bridge. Also in this case the yield of 
conjugation was comparable with the other conjugates and RP-HPLC was used 
for purification. 
All the conjugates presented a recovery of about 80%, as determined 
spectrophotometrically. 
 
 
Figure 4.10: Example of oligo and PEG-oligo RP-HPLC elution. Red line: a, green line: 
purified PEG-a. C18 Jupiter (5 µm, 300 Å, 250 x 4.60 mm), flow 1 mL/min, eluting with a 
non-linear gradient (A: 0.1 M TEAA, pH 7.0; B: ACN. 5 min 5% B, 20 min 40% B, 25 min 
40% B, 30 min 70% B, 50°C). 
 
 
4.2.2 Ligation whit T4 DNA ligase 
 
4.2.2.1 AFMF ligation and protocol optimization 
 
Before to perform the ligation with the PEGylated oligo, the enzymatic 
reaction was optimized with the not-pegylated oligos. Three different methods 
of annealing were tested to promote the maximum results of ligation and to 
avoid undesired products. 
After the annealing of the two double-stranded portions, an intermediate 
passage named “slow step” was added (see § 3.4.3.2). The two portions were 
mixed and kept at RT for 5 h. This time promoted the perfect pairing of the 
short sticky-ends of the components (AAT for AF and TTA for MF) that in not 
optimized conditions could also combine in a wrong way, leading to the 
formation of AF2/MF2. Figure 4.11 shows that under the selected conditions a 
single ligated product is obtained (lane 4). Instead, traces of unwanted products 
were found with the other two procedures (simple annealing in lane 3, “mix it 
— = a 
— = PEG-a 
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native PAGE, FAM signal native PAGE, EtBr staining 
all” annealing in lane 5). In fact, the formation of AF2 and MF2 in spite of the 
central missing base coupling in the overhang portions (A:A for AF2 and T:T 
for MF2) (Figure 4.11, lane 6 and 7) are reported. 
 
 
  
Figure 4.11: Different procedure of annealing pre-ligation of AFMF and AF2 and MF2 
formation proving. A) FAM signal; B) EtBr staining signal. Lane: 1, AF, 2, MF, 3, annealing 
procedure pre-ligation of AFMF, 4, annealing + “slow step” procedure pre-ligation of AFMF, 5, 
“mix it all” annealing procedure pre-ligation of AFMF, 6 and 7, AF2 and MF2 formation. 
Samples were applied on a 20% native PAGE containing 1X TBE buffer. The mobility of the 
ds oligos was detected using the Geliance 600 Imaging System. 
 
 
4.2.2.2 PEG-AMF ligation reaction 
 
PEG-AMF was prepared following the modified protocol settled for AFMF. 
To confirm PEG-AMF formation in DNA PAGE two characteristics is 
required: the FAM signal and a low electrophoretic mobility, the last caused by 
the hydrodynamic volume increased after PEGylation. 
In Figure 4.12 is shown the different electrophoretic mobility between the 
references and the PEGylated complex (lane 6); furthermore, high intensity of 
fluorescent signal is present at the base of the well, indicating that the ligation 
was successful. We also supposed that the polymer strongly stabilized the 
double-strand sequence because even in strong denaturing condition (panels C 
and D), the PEGylated complex was still in the double-stranded form and the 
mobility of the entire fluorescent ligate was very low. 
 
A B 
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Figure 4.12: PEG-AMF Ligation. A) native PAGE, FAM signal; B) native PAGE, Sybr 
Green II® staining; C) denaturing PAGE, FAM signal; D) denaturing PAGE, Sybr Green II® 
staining. Lanes: 1, a, 2, a', 3, m, 4, m', 5, mix PEG-AMF ligation, 6, PEG-A, 7, AF, 8, MF. 
Samples were applied on a 20% PAGE containing 1X TBE buffer. The mobility of the ds 
oligos was detected using the Geliance 600 Imaging System. 
 
 
4.2.2.3 PEG-AMF ligation reaction time course 
 
In order to increase the yield of ligation, PEG-AMF formation was 
monitored during the time at three different temperatures. As expected, DNA 
PAGE (Figure 4.14) and RP-HPLC data (Figure 4.13 and Table 4.4) suggested 
qualitatively and quantitatively that at the higher temperature the reaction was 
faster. At 21°C the ligation was complete after about 1 h. After this time only 
unwanted products were formed (especially MF2).  
 
A B 
C D 
native PAGE, FAM signal native PAGE, SbGII staining 
denaturing PAGE, FAM signal denaturing PAGE, SbGII staining 
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native PAGE, FAM signal native PAGE, EtBr staining 
 
Figure 4.13: PEG-AMF formation. Monitoring by RP-HPLC. Example of elution 
profile timing samples of 21°C experiment. C18 Jupiter (5 µm, 300 Å, 250 x 4.60 mm), flow 1 
mL/min, eluting with a non-linear gradient (A: 0.1 M TEAA, pH 7.0; B: ACN. 5 min 5% B, 20 
min 40% B, 25 min 40% B, 30 min 70% B, 50°C). λ= 494 nm. 
 
Table 4.4: PEG-AMF formation quantified by RP-HPLC. Data are calculated on the 
AUC of the PEG-AMF. o.n. time of each ligation (10°, 16° and 21°C).  
 0 min 10 min 20 min 30 min 1 h 2 h 3 h o.n. 
10°C 0.29 7.87 29.66 29.57 73.71 94.14 95.26 100 
16°C 7.75 18.31 52.32 68.13 78.21 82.42 82.82 100 
21°C 17.26 35.49 88.36 86.77 96.23 98.78 99.06 100 
 
   
A B 
— t = 0’ 
— t = 10’ 
— t = 20’ 
— t = 30’ 
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native PAGE, FAM signal native PAGE, EtBr staining 
native PAGE, FAM signal native PAGE, EtBr staining 
 
   
 
   
 
Figure 4.14: Time monitoring of PEG-AMF ligation at 21°C. Panels A), C) and E): 
FAM signal. Panels B), D) and F): Sybr Green II® staining. Lanes: 1, ref. PEG-A+MF, 2, t=0, 
3, t=10 min, 4, t=20 min, 5, t=30 min, 6, t=1h, 7, t=2h, 8, t=3h 9, t=o.n. Samples were applied 
on a 20% native PAGE containing 1X TBE buffer. The mobility of the ds oligos was detected 
using the Geliance 600 Imaging System. 
 
 
 
 
 
C D 
E F 
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4.2.3 EcoRI restriction 
 
To further confirm the effective ligation of the pegylated complex, the 
restriction enzyme EcoRI was used. Indeed, the couples of oligos were 
designed to form the EcoRI consensus sequence (GAATTC) after ligation. 
The reversible conjugate PEG-SS-a was prepared for this experiment with 
the aim to avoid potential steric entanglement by the PEG chain attached to the 
oligo. In fact after DTT treatment PEG is released from the DNA complex, 
which can then be treated with EcoRI. As shown in Figure 4.15, after reduction 
AMF is still present as the double-stranded fluorescenated AFMF (lane 5 and 
3). The enzyme EcoRI was active on AFMF and as expected on reduced PEG-
SS-AMF (AMF) but interestingly the enzyme was able to recognize and clive 
the substrate also in the PEGylated form (PEG-SS-AMF) (lane 6, 8 and 7 
respectively). 
 
 
 
 
Figure 4.15: Ligated DNA EcoRI restriction. FAM signal. Lanes: 1, AF+MF, 2, PEG-SS-
A+MF, 3, AFMF ligated, 4, PEG-SS-AMF ligated, 5, reduced PEG-SS-AMF (AMF), 6, 
restricted AFMF, 7, restricted PEG-SS-AMF, 8, reduced and restricted PEG-AMF. Samples 
were applied on a 20% native PAGE containing 1X TBE buffer. The mobility of the ds oligos 
was detected using the Geliance 600 Imaging System. 
 
 
4.2.4 PEG-BMF ligation reaction 
 
Once verified the capacity of DNA ligase to act on a PEGylated oligo 
complex, it has been important to verify if the enzyme could work also on 
PEGylated oligos with a reduced number of bases. The size of the oligos 
native PAGE, FAM signal 
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native PAGE, FAM signal native PAGE, SbGII staining native PAGE, EtBr staining 
denaturing PAGE, FAM signal denaturing PAGE, SbGII staining 
coupled to PEG was reduced by half, resulting in the 9-mer b with the 
complementary 12-mer b'. 
In Figure 4.16 it is shown that the fluorescent signal of PEG-BMF in the 
lane 4, which is compared with the non-PEGylated form BMF, has a very low 
electrophoretic mobility. This confirms that DNA ligase performed its action 
even when the distance between polymer site of coupling and the site of 
ligation is just 9 base pair. 
 
     
   
Figure 4.16: PEG-BMF Ligation. A) native PAGE, FAM signal, B) native PAGE, Sybr 
Green II® staining, C) native PAGE, EtBr staining, D) denaturing PAGE, FAM signal, E) 
denaturing PAGE, Sybr Green II® staining. Lanes: 1, b, 2, b', 3, MF, 4, mix PEG-BMF 
ligation, 5, mix BMF ligation. Samples were applied on a 20% PAGE containing 1X TBE 
buffer. The mobility of the ds oligos was detected using the Geliance 600 Imaging System. 
A B C 
D E 
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Since the early 80’s the forward steps in genetics and proteomics, have led a 
particular interest to biotech products, such as DNA and proteins. A better 
understanding of the molecular mechanism at the bases of pathologies and the 
large scale production of these molecules, help their success as therapeutics 
(Walsh, 2003). 
The strengths of proteins and genes are their high selectivity/affinity and 
high efficacy. Nevertheless, their pharmaceutical use presents some 
disadvantages, which may limit their use, such as the susceptibility to 
degradation by enzymes, rapid renal clearance and immunogenicity. 
Many researchers are seeking solutions in order to avoid these drawbacks, 
which include chemical modification or the use of drug delivery systems 
(DDSs). For proteins, some examples are genetic mutation, like amino acid 
substitutions and insertion of glycosilation sites, or formulation in DDSs. For 
oligos, chemical modifications of the backbone are the most used (for example 
at the level of ribose or phosphate group). 
One of the most successful DDSs is the covalent attachment of polyethylene 
glycol (PEG), also named PEGylation. It has become one of the most exploited 
approaches for the delivery of therapeutic proteins (Harris and Chess, 2003; 
Pasut and Veronese, 2007) and oligomers (Zhao et al., 2005; Zhao et. al, 2007; 
Ng et al., 2006). 
The advantages achieved by PEGylation can be summarized as follows: 
remarkable in vivo half-life prolongation (Pasut and Veronese, 2012), 
elimination or reduction of protein immunogenicity (Mero and Veronese, 
2008) and increased stability (Veronese et al., 2007). 
The effectiveness and potentials of this technique are demonstrated by the 
several conjugates already on the market, such as Neulasta®, Pegasys®, 
Mircera®, Cimzia® and others (see Table 2.1 and 2.2). On the other hand, PEG 
presents some weaknesses that might restrict its full exploitation; nevertheless 
it is still considered the polymer of choice. 
A known limit is its non-biodegradability, which was easily overcome by 
using polymers with molecular weights below the kidney excretion threshold. 
Furthermore, a recent concern comes from some studies reporting cases of 
development of specific anti-PEG antibodies. These were detected in the serum 
of patients treated with PEG-asparaginase (Armstrong et al., 2007) and PEG-
uricase (Sherman et al., 2008). Up to now, these events occurred only when the 
polymer was coupled to large and highly immunogenic proteins. Although the 
frequency of such reports is still limited, there is an unmet need of developing 
other polymers than PEG, offering a valid alternative that can also overcome 
the patent constrains of PEGylation. 
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A forward step in protein conjugation might occur by the use of 
biodegradable polymers. Such polymers can prevent protein limitations such as 
aggregation and fast kidney clearance, problems also solved by using non-
biodegradable polymers, but at the same time they can avoid the risks of 
polymer accumulation in the body. Furthermore, polymer degradation allows 
the recovery, at least in part, of protein activity that is usually reduced after 
polymer conjugation (Duncan et al., 2008; Hardwicke et al., 2008). 
Biodegradable polysaccharides, such as dextran, alginate, inulin, hyaluronic 
acid (HA), have been widely investigated as protein carriers. In the first 
studies, the conjugation strategies were based on random couplings between 
the protein’s amino groups and either the carboxylic groups of the polymer, if 
present, or aldehyde groups generated by periodate oxidation of the polymeric 
backbone (Torchilin et al., 1988). The main limitations of these approaches 
were undesired cross-linking, low homogeneity of conjugates and potential 
formation of soluble aggregates, which yielded difficulties in terms of 
characterization, batch-to-batch reproducibility and immunogenicity. 
In this respect, the first section of this work was focused on the potential 
role of a new HA-aldehyde derivative as carrier of proteins  
Hyaluronic acid is a natural polysaccharide largely present also in humans. 
HA has a relatively simple linear structure of repeating non-sulfated 
disaccharide units composed of D-glucuronic acid and N-acetyl-D-glucosamine 
(Almond, 2007).  
HA possesses several of the desired properties of a polymer for protein 
conjugation, such as biodegradability, non-immunogenicity and non-toxicity. 
In addition to the applications already in clinical use, HA has been thoroughly 
studied as carrier of low molecular weight drugs (Banzato et al., 2008). For the 
delivery of proteins, a multi reactive polymer can easily yield heavy cross-
linked conjugate mixtures with a high inhomogeneity. This limit prevents the 
direct use of HA for protein conjugation through activation of its carboxylic 
groups. 
The development of new HA derivatives for site selective protein coupling 
can circumvent this constraint and allows the exploitation of HA in this field. 
Polymers with aldehyde functionalities are the best choice for selective N-
terminal protein conjugation owing to their mild reactivity in comparison to 
other electrophile groups such as carboxy succinimidyl esters (Hu and Sebald, 
2011). 
Among all the different available chemical routes for introducing aldehyde 
groups into the HA backbone, in this study it was preferred a strategy that 
allowed the coupling of few HA carboxylic groups with 4-aminobutyraldehyde 
diethyl acetal. This approach offered several advantages. Firstly, the 
butyraldehyde group is less reactive than other aliphatic aldehydes, namely 
propyl or ethyl aldehydes (Hu and Sebald, 2011). 4-aminobutyraldehyde 
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diethyl acetal contains a protected aldehyde functionality that avoids the 
stability issue of aldehyde groups during long-term storage and it can be easily 
deprotected in the active form just before protein conjugation. Furthermore, the 
degree of derivatization can be well controlled and its determination in HA-
acetal batches can be straightforwardly evaluated by 1H-NMR, this offering a 
precise control over the reagents ratio in the following protein conjugation 
reaction. 
The new HA derivative was selectively linked to model proteins by 
exploiting the N-terminal conjugation. This method is based on the different 
pKa values between the N-terminal α amino group, about 7.6-8, and the ε 
amino group of lysines, about 10-10.2 (Wong, 1991). Another important 
advantage of the method is its suitability for almost all proteins. 
The potentials of this HA-acetal for protein conjugation (HAylation) and 
delivery were assessed with two model enzymes and the therapeutic 
polypeptide insulin. In the first case, the enzymes trypsin and RNase A offered 
the opportunity to investigate the effect of HA coupling on their enzymatic 
activity. The conjugation was performed at two pH values, 8.0 for random 
coupling at the level of lysines and 6.0 for selective protein N-terminus linking. 
Random conjugation was performed for an indirect evaluation of the steric 
hindrance and the flexibility of HA on the protein surface. In fact, the polymer 
chains might represent a great steric obstacle for the substrate recognition with 
the active site, an effect becoming more evident with the increase of the 
number of HA chains coupled per protein unit. But, the backbone flexibility 
may reduce in part the steric hindrance effect. 
Interestingly, HAylation determined only small reductions of enzymatic 
activities, this being always above 70% on small substrates for both trypsin and 
RNase A. As expected, the activity reduction was more significant when 
measured with large substrates (casein for trypsin) but still it is above 53% 
even for rHA-trypsin. These results indicate that the polymer does not 
completely hinder the approach of even large substrates to the catalytic site, 
likely thanks to its backbone flexibility and hydrophilicity. Anyway, N-
terminal conjugates were more active compared to random ones. 
The thermal stability studies showed that HAylation does not cause 
detrimental effects on protein structure over the time after incubation at 37°C 
in physiological buffer. In fact, the activity of HA-Nter-RNase A was 
comparable to that of the native enzyme. In the case of trypsin, the polymer 
markedly increased enzyme stability because HAylation reduced the typical 
autolysis process, an effect seen also after conjugation with other polymers 
(Gaertner and Puigserver, 1992). 
HA is a biodegradable polymers and this represents a relevant advantage 
over the most used polymer in this field, PEG, which is non biodegradable 
(Pasut et al., 2008). It was therefore important to verify if hyaluronidase, the 
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enzyme involved in HA degradation in vivo, was still able to degrade HA after 
its conjugation to a protein. Figure 4.5 shows that the HA moiety of conjugates 
is digested by hyaluronidase thus confirming the biodegradability of the 
polymer also after conjugation. This feature offers the possibility to prepare 
conjugates that in vivo are slowly digested into protein conjugates with short 
HA chains that should allow a recovery of the protein activity lost after 
HAylation. 
After testing and optimizing the conjugation of HA to model enzymes, the 
HA-acetal derivative was used to prepare a potential therapeutic conjugate with 
insulin and the conjugates were studied in vivo. 
In this case two HA-acetal batches, differing in the degree of acetal 
substitution (4 and 21%), were used to investigate also the effect of protein 
loading. The percentages of aldehyde groups in the HA backbone correlates, 
although not proportionally, with the insulin loading in the final conjugates, 
17.2% and 32% (w/w) for HA-Nter-INS 1 and HA-Nter-INS 2, respectively, 
thus suggesting a steric hindrance between the polypeptide chains.  
Unexpectedly, the in vivo study in diabetic rats showed that HA-Nter-INS 1 
had an enhanced hypoglycemic activity with respect to HA-Nter-INS 2. In fact, 
in the case of HA-Nter-INS 1 the lowering effect on blood glucose level was 
maintained for more than 6 h when, in comparison, insulin exhausted its effect 
after 1 h. 
Conversely, HA-Nter-INS 2 was even less effective than insulin. Probably 
the higher insulin loading of HA-Nter-INS 2 led to a steric entanglement 
affecting the receptor/protein recognition. On the other hand, it is also possible 
that the greater loading, which yielded a bigger conjugates, hampered the 
diffusion from the site of s.c. injection to the blood stream, although the 
glucose level was monitored for up to 24 h. 
Nevertheless, the prolonged and enhanced hypoglycemic effect of the HA-
Nter-INS 1 conjugate, compared to free insulin, revealed that HA conjugation is 
able to modify the PK profile of proteins by increasing their half-lives and 
behaving as a depot system. All these findings encourage the use of HAylation 
technology for the conjugation of proteins of pharmaceutical interest. 
Summarizing, HAylation performed with this new HA-acetal derivative 
demonstrated great potentialities of development for protein delivery. The 
obtainment of a stable and easily characterizable HA derivative, suitable for 
site selective protein conjugation, was a prerequisite for the full exploitation of 
the biodegradability advantage of HA over the most known polymer in the 
field of protein conjugation, PEG (Mero, et al., 2013). The biodegradability of 
HA backbone, preserved after protein conjugation, should represent one of the 
main strength of HA because it allows the release of protein conjugates with 
short HA oligomers in vivo, thus allowing at least a partial recovery of protein 
activity. On other hand, it should be highlighted that HAylation might not be 
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suitable for immunogenic proteins because, for the same reason reported 
above, it would not offer a complete shielding of immunogenic sites over the 
time.  
In conclusion, the results presented in this study warrant further broader and 
thoroughly investigations of HAylation. Other in vivo studies on HA 
conjugation with therapeutic proteins are presently under way in our lab for 
thoroughly investigating the in vivo behavior of several conjugates. 
 
As mentioned above, closely to proteins, oligonucleotides are very 
promising molecules as future therapeutics. They are mainly involved in the 
treatment of tumour and genetic diseases.  
Likewise to proteins, the therapeutic use of oligos has some limitations. 
First of all the short plasma clearance. Other oligos characteristic can also limit 
their administration, for example the strong and marked negative charge, the 
long sequences and the difficulty to reach the site of action (the nucleus). In 
order to overcome these restrictions, once again DDSs can be helpful, 
enhancing for example nucleus targeting and acting as a protecting-shield from 
circulating enzyme degradation (Merdan et al., 2002; Ruponen et al., 2003). 
Particular cases of short oligomers are represented by aptamers and 
ribozymes. They consist mainly of RNA but their functions are strongly related 
to proteins. Instead to represent, as usual, a copy of DNA responsible for the 
synthesis of proteins, they act as an antibody and an enzyme, respectively. 
The most known aptamer is MACUGEN® (pegaptanib), already in the 
market since the 2004, an anti-VEGF PEGylated aptamer (FDA P04-110; 
EMA/671614/2010; EMEA/H/C/000620), used in the treatment of new 
vascular age-related macular degeneration (Ng et al., 2006). In fact, as 
mentioned for PEG-proteins, PEGylation of oligomers has shown several 
advantages: prolonged half-life, low enzyme degradation, less administration 
frequency (Zhao et. al., 2005; Zhao et. al., 2007).  
In the second section of this work it was investigated an innovative 
PEGylation strategy for oligo sequences, based on an enzymatic-mediated 
conjugation. Differently from many classical conjugation syntheses, the 
enzymatic ligation is conduct in mild condition, always maintaining a stable 
environment for the oligomers. 
PEG is available with many functionalizations, but no function is useful for 
our purpose to enzymatically join the polymer to an oligo. To overcome this 
issue, a short DNA sequence was attached to the polymer. The DNA sequence 
was modified with an -SH reactive group in 5’-ending and thiol-reactive PEGs 
(mPEG20kDa-Mal and mPEG20kDa-OPSS) were used for the linkage. 
The selected enzyme was T4 DNA ligase, which catalyzes the formation of 
a phosphodiester bond between juxtaposed 5’ phosphate and 3’ hydroxyl 
termini in duplex DNA or RNA. This enzyme is able to join blunt or cohesive 
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end termini as well as repair single stranded nicks in duplex DNA, RNA or 
DNA/RNA hybrids (Engler and Richardson, 1982). 
To study the enzymatic PEGylation, a ligation model was appositely design, 
composed of four reference DNA sequences (Table I.I; a 18-mer, a' 21-mer, m 
19-mer, and m' 16-mer). As required by the enzyme, the four oligos match in 
two complementary pairs (A, a + a'; MF, m + m'), in this case both ending 
with sticky-ends complementary in turn (AAT and TTA, respectively). In 
particular, a was modified at the 5’-termini with a thiol group for PEGylation. 
As expected, PEG-a synthesis was easy and fast and purification by RP-
HPLC gives good yield, always around 80%. 
After verifying the correct functionality of ligase (on AFMF), some 
modifications to classic protocols allowed to obtain excellent results with the 
PEGylated oligo: complete PEG-AMF ligation and absence of undesired 
products. 
Ligation products were resolved by DNA-PAGE in native and denaturing 
condition, showing for PEG-AMF a characteristic fluorescent band at the base 
of the walls. This is explained by the very low electrophoretic mobility of the 
PEGylated sequences and the 6-FAM modified m'. In the denaturing 
migration, it was expected to find two different bands for PEG-AMF: a non-
fluorescent band for PEG-am and a fluorescent one for a'm'. In fact, generally 
denaturing condition separates a double-strand sequence in the two 
complementary homologues. Despite 7M urea condition, no difference with 
native electrophoretic migration were shown, proving a strong stabilization of 
the double-stranded sequence by PEGylation. 
PEG-AMF ideal conditions were then defined monitoring the reaction 
during the time at different temperatures. Despite the short length and the 
consequently low melting temperature, the best results were obtained at 21°C 
for 1 hour. 
To further confirm the effective ligation, the PEGylated and ligated 
sequence was restricted with EcoRI enzyme. Indeed, the EcoRI consensus 
sequence (GAATTC) was formed only after ligation. In particular, reversible 
conjugate PEG-SS-a was prepared for this experiment with the aim to avoid 
potential steric entanglement by the PEG chain attached to the oligo. After 
ligation, in a part of the mixture the polymer was removed by DTT treatment. 
As expected, EcoRI was active on the reference AFMF and the reduced PEG-
SS-AMF (AMF), but interestingly the enzyme was able to recognize and cleave 
its specific substrate also in the PEGylated form (PEG-SS-AMF). This 
evidence further confirms that a PEG chain attached to the reference model 
does not modify its susceptibility to enzymatic reaction. 
Furthermore, it has been important to verify if the DNA ligase activity could 
be affected by PEGylated oligo with a reduced number of bases. Thus, the 
PEGylated portion A was been reduced by half into B (b 9-mer and b' 12-mer). 
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As described for a, also b was modified with a thiol group in 5’-ending 
position and exploited for polymer conjugation. Even with a so short 
PEGylated sequence the model was efficiently ligated, resulting in complete 
PEG-BMF. 
Summarizing, a model of enzymatic PEGylation for double-stranded DNA 
sequence was optimized, involving T4 DNA ligase enzyme. This model was 
well characterized and standardized, so potentially applied to every DNA 
sequence (but appositely modified for complementary sticky-ends). This 
method can be considered an innovative approach in PEGylation, because of 
the enzymatic mediated coupling and the potential reversibility of the process, 
with the possibility to remove the polymer if it is necessary (by chemical 
reduction of the disulfide bond or enzymatically). Moreover, it was proved that 
PEGylation strongly stabilized the ds-sequences even in strong denaturing 
condition. 
Furthermore, a PEGylated 9-mer was chosen in order to better investigate if 
T4 DNA ligase could also works closely to the site of PEGylation, confirming 
that it was still active. At the same time, a short PEGylated oligo means a cost 
reduction. 
This easy method, with the improved characteristics of PEGylated DNA 
sequences, offers new possibilities in the use of oligos in diagnostic and 
therapeutic field. 
A future proposal for this approach is the substitution of DNA ligase with 
RNA ligase, in order to involve also single-strand oligo and enrich the 
applications. 
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